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ABSTRACT 
Chronic pain is a major health issue worldwide. It enacts considerable suffering on the affected 
individuals and significantly increases the societal burden, as it is the most common reason 
why individuals seek sick leave and ask for medical help. Pharmacotherapies for chronic pain 
are not satisfactory, and many patients, despite taking medications, do not find relief and end 
up using opioids. Long-term opioid use carries with it numerus adverse effects, including but 
not limited to opioid induced hyperalgesia (OIH), tolerance, dependence (addiction) and 
opioid-related deaths. OIH is defined as a state of nociceptive sensitization, i.e. a state of 
becoming more sensitive to painful stimuli when using opioids for a long time. Cellular and 
molecular mechanisms that underlie OIH are still not fully understood, and efficient treatment 
strategies that retain the analgesic effects of opioids, while reducing this negative side effect 
are therefore underdeveloped. 
Clinical studies in healthy subjects and  patients with fibromyalgia, a chronic pain syndrome 
with abnormalities in cerebral opioid signaling, have implicated interactions between the mu-
opioid (MOP) and the serotonin 1A (5-HT1A) receptors in descending pain modulatory circuits 
as important for chronic pain modulation. Preclinical studies have shown that co-treatment with 
5-HT1A agonists reduces OIH, diminishes the rewarding effects of morphine and the 
development of opioid tolerance. They have also provided indirect evidence for the co-
localization of MOP and 5-HT1A receptors in the same nerve terminals, and demonstrated that 
MOP and 5-HT1A synergistically inhibited GABA release in the periaqueductal gray (PAG), a 
structure that mediates opioid-based pain control. Based on these findings, it was proposed that 
MOP and 5-HT1A heterodimerization is a potential mechanism through which MOP- and 5-
HT1A-mediated signaling pathways are interlinked. It is further hypothesized that MOP and 5-
HT1A heterodimer formation alters cellular signaling and contributes to neuroplastic changes 
that, eventually, lead to sensitization of pronociceptive pathways at the organism level. 
However, while co-localization of MOP and 5-HT1A receptors in discrete brain and spinal cord 
regions is well documented, the existence of heterodimers between MOP and 5-HT1A receptors 
has, thus far, only been shown in one study, which relied on the use of co-immunoprecipitation 
and Bioluminescence Resonance Energy Transfer (BRET) to demonstrate that these 
heterodimer complexes could form. 
The primary objective of my PhD studies was to challenge the hypothesis that prolonged 
exposure to non-peptide opioids promotes heterodimer formation between MOP and 5-HT1A 
receptors, and that this effect can be abolished by co-treatment with 5-HT1A agonists. To this 
aim, cell lines of human and rat origin where genetically transformed to stably express 
physiologically relevant levels of MOP and 5-HT1A receptors tagged with spectrally distinct 
fluorescence reporters. Fluorescence Cross-Correlation Spectroscopy (FCCS), the dual color 
variant of the quantitative and nondestructive analytical technique called Fluorescence 
Correlation Spectroscopy (FCS), was used to characterize the receptor-receptor interactions in 
live cells. Additionally, confocal laser scanning microscopy (CLSM) was used to map the 
consequences of non-peptide opioid treatment on Ca2+ signaling dynamics and western blotting 
was applied to investigate signaling cross-talk via mitogen-activated protein kinases (MAPKs) 
p38 and the extracellular signal-regulated kinase (ERK1/2).  
The work presented in this thesis, summarized in papers I-V, has contributed to better 
understanding of important basic cellular and molecular mechanisms that underlie signal 
transduction and material uptake across the plasma membrane. In particular, the work 
presented in papers I-III focuses on cellular and molecular mechanisms that underlie the 
development of OIH. In Paper I, we have shown that prolonged exposure to non-peptide 
opioids facilitates heterodimer formation between MOP and 5-HT1A receptors in live cells 
expressing physiologically relevant receptor levels. The extent of receptor heterodimerization 
was found to be both, opioid-specific and dose-dependent. Furthermore, we have shown that 
different opioids differently affected second messenger pathways, as indicated by differences 
in Ca2+ signaling dynamics and differential activation of p38 and ERK1/2 MAPKs. In Paper 
II, we have shown that 5-HT1A agonists such as buspirone and three newly identified buspirone 
analogs: B2, B3 and B5, can effectively reverse MOP–5-HT1A heterodimerization, thus 
counteracting the aversive effects of morphine. Importantly, this study, which brought together 
molecular modeling, virtual screening and advanced experimental tests in live cells, may in 
the future lead to the development of new drugs that target MOP and 5-HT1A heterodimer 
formation. In paper III, we have quantitatively characterized using FCS/FCCS and 
PhotoActivated Localization Microscopy (PALM) the nanoscale lateral dynamics and spatial 
organization of wild type MOP and its naturally occurring isoform (MOPN40D). We have shown 
that this non-synonymous single-nucleotide polymorphism (SNP) in the OPRM1 gene 
encoding the MOP, which is known to confer pain- and substance abuse-specific phenotypes 
at the organism level, significantly affected the lateral dynamics and organization of MOPN40D 
at the nanoscale level. In particular, we found that MOP-containing domains were larger and 
more densely populated than the MOPN40D harboring domains, with a small fraction of 
molecules residing outside of nanodomains. The opposite was found for MOPN40D. Moreover, 
we found that cholesterol depletion dynamically regulated the partitioning of MOP but not of 
MOPN40D, and observed that MOP and MOPN40D differ with respect to opioid peptide-induced 
internalization, with MOP being readily internalized together with the opioid peptide upon 
  
stimulation with -endorphin, whereas MOPN40D showed lower internalization propensity and 
was typically not internalized together with the opioid peptide. These apparently subtle 
differences at the nanoscale level may, at least in part, explain why differences with respect to 
opioid dependence and analgesia are observed at the organism level.  
Papers IV and V describe collaborative work where CLSM and/or FCS/FCCS were used 
to characterize translocation across the plasma membrane and cellular uptake. In Paper IV, we 
focus on substance delivery using cell-penetrating peptides as a vehicle. Using FCS/FCCS, we 
revealed the heterogeneity underlying self-assembly of cell-penetrating peptides and 
oligonucleotides, in this case small interfering RNA (siRNA), into large molecular complexes. 
We showed that peptide monomers, peptide self-aggregates and polydisperse peptide/cargo 
complexes coexist in solution and in live cell plasma membrane, which could explain why 
diverse cellular uptake mechanisms were simultaneously observed for cell-penetrating 
peptides-based delivery of cargo molecules. In Paper V, CLSM imaging was used to examine 
the role of α-Gal carbohydrate on protein uptake and degradation by immature monocyte-
derived dendritic cells (iMDDCs), as a potential cellular and molecular mechanisms underlying 
the development of allergy to red meat. CLSM imaging revealed that presence of allergenic α-
Gal epitopes on the protein surface significantly increases the uptake of the investigated model 
antigens, BSA-α-Gal and HSA-α-Gal, by in vitro cultured human iMDDCs, and showed that 
the taken up proteins are processed in endosomes.  
 
  
ABSTRAKT 
Kronisk smärta är ett viktigt hälsoproblem världen över. Det orsakar inte bara lidande för de 
drabbade, utan orsakar även stora samhällsekonomiska belastningar då det är den vanligaste 
orsaken till sjukfrånvaro och läkarbesök. Behandlingar för kronisk smärta är sällan 
tillfredsställande och många patienter finner inte lindring trots första linjens medicinering, 
vilket resulterar i behandling med opiater. Långtidsbehandling med opiater bär med sig ett 
flertal ogynnsamma effekter som opioidinducerad hyperalgesi (OIH), tolerans, beroende 
samt opioidrelaterade dödsfall. OIH definieras som ett tillstånd av nociceptiv sensibilisering 
(ett tillstånd av ökad känslighet för smärtsamma stimuli) till följd av långtids opioidbruk. De 
cellulära och molekylära mekanismer som underligger OIH är ännu inte fullt klargjorda, 
således är effektiva behandlingsstrategier som bibehåller den analgetiska effekten av opioider 
samt minimerar deras biverkningar underutvecklade.  
Kliniska studier på friska subjekt samt patienter med fibromyalgi (ett kroniskt smärtsyndrom 
med abnormal cerebral opioidsignalering) har påvisat interaktioner mellan mu-
opioidreceptorn (MOP) och serotonin-1A-receptorn (5-HT1A) i nedåtgående 
smärtmodulering som viktiga inom kronisk smärtmodulering. Prekliniska studier har visat att 
sambehandling med 5-HT1A-agonister och opioider reducerar OIH, minskar de belönande 
effekterna hos morfin samt utvecklingen av tolerans. Dessa studier har också indirekt påvisat 
att MOP och 5-HT1A samlokaliserar i samma nervterminaler, samt demonstrerat att MOP och 
5-HT1A synergistiskt hämmar GABA-utsöndring i det periakveduktala grå substansen (PAG), 
en struktur som medierar opioidbaserad smärtkontroll. Utifrån dessa rön har det föreslagits 
att heterodimerisering mellan MOP och 5-HT1A är en möjlig mekanism genom vilken MOP-
5-HT1A-medierad signalering är sammankopplad. Det är vidare hypotetiserat att 
heterodimerisering mellan MOP och 5-HT1A förändrar cellulär signalering och bidrar till 
neuroplastiska förändringar som slutligen leder till sensibilisering av pronociceptiva banor 
på organismnivå. Även om samlokalisationen av MOP och 5-HT1A i diskreta delar av hjärnan 
och ryggraden är väldokumenterade så har endast en tidigare studie lyckats påvisa 
heterodimerisering mellan MOP och 5-HT1A. Studien förlitade sig på metoderna 
samimmunoprecipitation och bioluminescence resonance energy transfer (BRET) för att 
påvisa bildningen av heterodimerer. 
Det huvudsakliga målet för mina doktorandstudier var att undersöka hypotesen att långvarig 
exponering för ickepeptida opioider främjar bildandet av heterodimerer mellan MOP och 5-
HT1A och att denna effekt kan omvändas via sambehandling med 5-HT1A-agonister. För detta 
ändamål har cellinjer med ursprung från både människa och råtta genetiskt omvandlats för 
  
att uttrycka fysiologiskt relevanta nivåer av både MOP och 5-HT1A, märkta med spektralt 
distinkta fluoroforer. Tvåfärgsvarianten av den kvantitativa och oförstörande analysmetoden 
fluorescence correlation sprectroscopy (FCS), känd som fluorescence cross-correlation 
spectroscopy (FCCS), var tillämpad för att karakterisera interaktionerna mellan de två 
receptorerna i levande celler. Konfokal laserskanningsmikroskopi (CLSM) användes för att 
kartlägga effekten av dessa interaktioner på kalciumsignalering, medan analys via Western 
Blot användes för att undersöka signalöverförning (cross-talk) via mitogenaktiverade 
proteinkinaser (MAPKs), p38, samt extracellulärt signalregulerande kinas (ERK1/2).  
Arbetet som presenteras i denna avhandling (sammanfattat i publikationerna I-V) har bidragit 
till en bättre förståelse  av viktiga grundläggande cellulära och molekylära mekanismer. Det 
arbete som presenteras publikationerna I-III fokuserar på de cellulära och molekylära 
mekanismer bakomliggande utvecklingen av OIH. I publikation I påvisar vi att långvarig 
exponering för icke-peptida opioider främjar bildandet av heterodimerer mellan MOP och 5-
HT1A, i celler som uttrycker fysiologiskt relevanta nivåer av receptorerna. Utsträckningen av 
receptorheterodimeriseringen påvisades vara både beroende av opioidtyp och -dos. Utöver 
det kunde vi påvisa att olika opioider påverkade second messenger signaltransduktionsvägar 
olika, då de påverkade kalciumsignalering, p38, och ERK1/2 olika. I publikation II visade 
vi att 5-HT1A-agonister, så som buspiron och tre nyligen identifireade buspironanaloger (B2, 
B3, och B5), hade omvänd effekt på MOP-5-HT1A-heterodimerisering och således 
motverkade morfininducerad heterodimerisering. Denna studien band samman 
molekylärmodelering , virtuell undersökning och avancerade experimentella försök i levande 
celler. Den kan i framtiden vara gynnsamt för utvecklingen av nya läkemedel riktade mot 
MOP-5-HT1A-heterodimerisering. I publikation III har vi kvantitativt karakteriserat den 
spatiala organisationen av MOP och den naturligt förekommande isoformen MOPN40D via 
FCS/FCCS och PhotoActivated Localization Microscopy (PALM) och påvisat att dessa 
egenskaper är viktiga determinanter för opioidreceptorers funktion. Vi fann att denna punkt 
mutation (single-nucleotide polymorphism) i OPRM1 genen, som kodar för MOP, ändrade 
den laterala dynamiken och organisationen hos MOPN40D, på ett signifikat vis. I synnerhet 
fann vi att MOP-berikade domäner var betydligt mer tätbefolkade än domäner som innehöll 
MOPN40D, med en bråkdel av molekylerna utanför dessa domäner. Det motsatta visade sig 
gälla för MOPN40D. Tömning av kolesterol regelerade dyamiskt fördelnignen av MOP, men 
inte av MOPN40D. Dessa subtila skillnader på nanonivå kan förklara varför signifikanta 
skillnader i  opioid beroende och analgesi kan ses på organismnivå. I publikation 
IV tillämpades FCS/FCCS  för att påvisa den heterogena naturen av cellpenetrerande 
peptiders samt nukleotiders (siRNA i detta fallet) självuppbyggande. Vi visade att 
peptidmonomerer, peptid självaggregerade och polydispersiva peptid/frakt komplex 
existerade samtidigt i lösning samt i cellers plasmamembran, vilket kunde till viss del förklara 
varför olika upptagningsmekanismer hos cellern kunde noteras vid cellpenetrerande 
peptidbaserad leverans av fraktmolekyler. I publikation V undersökte vi de cellulära och 
molekylära mekanismerna bakom köttallergi, med fokus på kolhydraten α-Gals roll i 
proteinupptag och nedbrytning i immature monocyte-derived dendritic cells (iMDDCs). 
CLSM visade att α-Gal-epitopen på proteiners yta signifikant ökade upptaget av de 
undersökta modellallergenerna BSA-α-Gal och HSA-α-Gal i odlade humana iMDDCs och 
att de upptagna allergenerna bearbetas i endosomer. 
  
  
LIST OF SCIENTIFIC PAPERS 
I. Vlad Radoi, Gerd Jakobsson, Vinko Palada, Henrik Druid, Lars Terenius, 
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1 INTRODUCTION 
The interdisciplinary work presented in this PhD thesis addresses an important basic challenge 
in medicine, the pharmacotherapy of chronic pain. By examining cellular and molecular 
mechanisms that underlie the development of opioid induced hyperalgesia (OIH), this thesis 
seeks to quantitatively characterize interactions between two important receptors in order to 
assess their potential to serve as targets for the development of successful pharmaceutical 
approaches for the treatment of chronic pain.    
 
1.1 A BRIEF OVERWIEV OF PAIN ANATOMY AND PHYSIOLOGY  
 
1.1.1 General pathways of pain sensation  
Pain, an unpleasant sensory and emotional feeling that results from physical and psychological 
responses to injury, is conveyed through a complex set of cellular and neurochemical 
interactions, i.e. pathways that bring together the functions of cells in specific regions in the 
brain, midbrain, the spinal cord and the periphery. While there are many types of pain, which 
differ in their underlying cellular and molecular mechanisms, as briefly discussed below, it is 
useful to begin by recapitulating the basics of normal pain physiology.  
Briefly, under normal physiology, pain is transmitted and modulated through two principal 
routes, or pathways through which information flow in opposite directions. Pathways through 
which painful stimuli are being conveyed from the place of injury to the somatosensory cortex, 
part of the cerebral cortex where the information is integrated and the perception of pain is 
being perceived, are called nociceptive or ascending pathways. Pathways through which 
painful stimuli are controlled and modulated, are called anti-nociceptive or descending 
pathways (Fig. 1).  
The very first step in pain transmission is called transduction, and refers to the process by which 
tissue-damaging stimuli, mechanical, chemical or thermal, activate nerve endings. For 
example, at the site of a peripheral injury damaged cells release various molecules. Thinly 
myelinated and unmyelinated sensory neurons respond to these molecules and carry the 
information through the peripheral branch of their axon to the dorsal root ganglion (DRG), 
where their somas are located, and thereafter through the central branch of their axon to the 
dorsal horn of the spinal cord. As the sensory neurons are the first in line to receive information 
about tissue injury, they are also called 1st order neurons. Within the dorsal horn of the spinal  
 2 
 
Figure 1. Schematic drawing of the integration of pain pathways at the organism level. Nociceptive inputs 
from damaged cells are transmitted through sensory neuron fibers, 1st, 2nd and 3rd order neurons comprising the 
ascending pathway (ocher) to the somatosensory cortex where the feeling of pain is being perceived. The 
descending pathways (red) originate in the somatosensory cortex, which relays to the thalamus. Thalamic neurons 
descend to the midbrain, where they synapse on ascending pathways in the medulla and the spinal cord and inhibit 
ascending nerve signals, thus soothing pain and producing pain relief (analgesia). Insert in the lower right corner 
shows key cells and molecules through which pain modulation is being achieved in the spinal cord, with a 
particular emphasis on the effective pain inhibition through the action of serotonin (5-HT) and opioid peptides. 
Inset in the upper right corner shows schematic drawing of the brainstem with most important functional regions 
depicted (see text). The image was generated using material from PAIN! Physiology - The Ascending Pathway, 
Descending Pain Pathway and the Substantia Gelatinosa (https://www.youtube.com/watch?v=5c8maFAhqIc), 
with kind permission from the Author. Inset, upper right: Image https://images.app.goo.gl/mLvBqnyoetkiofBLA, 
from: Lin, T. (2016). Physiology of pain. In C. Mowatt (Author) & T. Lin, T. Smith, & C. Pinnock (Eds.), 
Fundamentals of Anaesthesia (pp. 431-453). Cambridge: Cambridge University Press. 
doi:10.1017/9781139626798.023 reproduced with permission from the Publisher.   
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cord, the 1st order neurons form synapses and relay the signal to another set of neurons, called 
2nd order neurons, by releasing substance P, an 11 amino acids long neuropeptide from the 
tachykinin family. 
The 2nd order neurons cross over to the other side of the dorsal horn and enter a region 
called the spinothalamic tract (Fig. 1, ocher). From the spinothalamic tract, the 2nd order 
neurons ascend through the spinal cord and the brain stem, and terminate in the thalamus, with 
lateral projections targeting mesencephalic nuclei, including the dorsal reticular nucleus (DRt), 
the rostral ventromedial medulla (RVM) and the midbrain periaqueductal gray (PAG). In the 
thalamus, the 2nd order neurons form synapses with 3rd order neurons, which will carry on the 
information to a specific region in the cortex that is related with the site of injury. Thus, the 3rd 
order neurons help to discern the area of injury and convey the information to the relevant 
region of the somatosensory cortex where the information about the injury is being perceived. 
The descending pathway starts in the somatosensory cortex, which relays to the thalamus 
and the hypothalamus (Fig. 1, red). Thalamic neurons descend to the midbrain, more precisely 
to the midbrain PAG. These neurons project to the nucleus raphe magnus (NRM) in the brain 
stem medulla, where they form synapses with serotonergic/noradrenergic neurons that secret 
serotonin (5-hydroxytryptamine, 5-HT) and noradrenaline (NA, also known as 
norepinephrine). The 5-HT/NA neurons project to the dorsal horn, more precisely to the 
substantia gelatinosa in the dorsal horn, where the synapses between the 1st and 2nd order 
neurons are located, which is also richly populated with other cell types, most notably opioid 
interneurons (Fig. 1, blue). Secreted 5-HT and NA suppress substance P release from the 1st 
order neurons and activate the opioid interneurons, which respond by secreting endogenous 
opioid peptides. Opioid peptides exert a dual action: (1) inhibit substance P release from the 
pre-synaptic 1st order neurons and (2) inhibit the depolarization of post-synaptic 2nd order 
neurons, thus effectively blocking the propagation of pain signal through the ascending 
pathway. 1-8 
1.1.2 Nociceptive and neuropathic pain 
While classification of pain is not easy, as there are many aspects according to which 
distinctions could be made and differences between classes are not clear-cut, it is rather 
straightforward to distinguish two types of pain, nociceptive and neuropathic pain. Nociceptive 
pain is normal physiological response that results from neural pathway activation by a potential 
or actual tissue damage 9. Nociceptive pain is therefore protective. Neuropathic pain is, on the 
other hand, caused by damage to the nervous system. It is, thus, a pathological process that 
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arises without a known, immediately preceding cause and with no need for outside stimuli to 
be involved 9,10. Neuropathic pain reflects a dysfunctional nervous system, and therefore may 
arise through a variety of different mechanisms. For example, damage to inhibitory pathways 
or excessive stimulation of nociceptive pathways can shift the balance between non-noxious 
and noxious sensory input in such a way that pain arises without there being any noxious 
stimuli9,11.     
Furthermore, pain can be classified with respect to duration and onset. 
 
1.1.3 Acute pain 
Acute pain is a physiologically normal and healthy response to offensive stimuli. It can be 
directly related to a cause, is of short duration and gradually resolves as the injured tissues heal. 
It enables an organism to detect when normal homeostasis has been disrupted and to modify 
its behavior as the need dictates 7. Thus, it is a protective, warning mechanism that 
communicates to the individual to withdraw from harmful stimuli 7,8. The pain transmission 
mechanism succinctly described in subsection 1.1.1, outlines key steps in acute pain 
transmission. It is, however, important to bear in mind that qualitative and quantitative tissue-
specific differences at a more detailed level of description exist 7.  
Acute pain can be treated at different levels of organization of the pain transmission system. 
For example, pain transduction, i.e. conversion of the noxious stimulus to electrical signals, 
which is the initial step in pain transmission, can be inhibited by nonsteroidal anti-inflammatory 
drugs (NSAIDs, such as aspirin or ibuprofen) 12, opioids or local anesthetics (consisting of a 
hydrophilic tertiary amine and a lipophilic aromatic system combined by an ester or an amide 
linkage) 13. Pain propagation through the peripheral nervous system via 1st order neurons, i.e. 
transmission, can be reduced by local anesthetics and agonists at the alpha2-adrenergic receptor 
(e.g. clonidine, tizanidine, dexmedetomidine) 14. Modulation of interactions between 1st and 
2nd order neurons in the dorsal horn cells of the spinal cord can be influenced by local 
anesthetics, alpha2-adrenergic receptor agonists, opioids, NSAID’s, tricyclic antidepressants 
(TCAs) and NMDA receptor antagonists 15. Finally, perception, i.e. the cerebral cortical 
response to nociceptive signals projected by 3rd order neurons, can be inhibited by general 
anesthetics, opioids and alpha2-adrenergic receptor agonists 15-17. 
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1.1.4 Chronic pain 
Chronic pain is a serious health issue worldwide. It not only generates considerable suffering 
for those affected, but also generates economic burdens for both, the patient and the society 3,8, 
as it is among the top ten causes of disability in the world 18. Chronic pain is defined as an 
unpleasant sense of discomfort that persists or recurs over long time, typically longer than 3 to 
6 months. Chronic pain often presents as result to disease or injury, but is not viewed as only 
an accompanying symptom or an affliction, rather as separate condition 18, whereas, acute pain 
is viewed as a physiologically normal and healthy response 7. When pain is persistent, pain 
transmitting components of the peripheral and central nervous system display great plasticity, 
which in turn leads to elevated pain signaling and generates hypersensitivity. This plasticity 
can be advantageous, as it promotes protective reflexes. It is when this persists that a chronic 
pain state may develop 6,19. The reason why acute pain sometimes can transition into a chronic 
state has yet to be fully understood. A hypothesis gaining a lot of ground is neuroinflammation 
and, subsequent, glial cell activation as a key mechanism of acute pain transitioning to a chronic 
state 19,20. By converting from resting state to a hyperactive state, glial cells, microglia and 
astrocytes exhibit a dynamic plasticity 2,19. Mitogen-activated protein kinases (MAPKs) have 
been indicated as crucial mediators in intracellular cascades, during glial activation. MAPKs 
includes three main kinase family subtypes, namely ERKs, p38 and c-jun N-terminal kinases 
(JNKs) 3,16,21.  
The most common treatments for nociceptive pain are opioids 13, nonsteroidal anti-
inflammatory drugs (NSAIDs), paracetamol 12. Common treatments for neuropathic pain 
include anticonvulsants and antidepressants 22. Opioids are most commonly used to elevate 
severe pain 13. Acute and chronic pain differ in their response to pharmacotherapy, with chronic 
pain often being nonresponsive to treatment with commonly used analgesics 3-8. Despite their 
limited effects for treatment of chronic pain, patients with chronic pain are often prescribed 
analgesics, including opioids. The analgesic properties of opioids have been known for 
thousands of years and while their effect is well recognized for acute/subacute nociceptive pain 
conditions, their role in chronic pain remains controversial 23,24. Opioids elicit side effects, 
which include respiratory depression, vomiting, nausea and constipation. The major concern 
for chronic pain patients, however, is tolerance build up, opioid induced hyperalgesia (OIH) 
and withdrawal 1,25. 
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1.2 MOLECULAR BASIS OF PAIN – FOCUS ON G PROTEIN-COUPLED 
RECEPTOR REPRESENTATIVES MOP AND 5-HT1A  
G protein–coupled receptors (GPCRs) constitute the largest superfamily of transmembrane 
receptors. Members of this family share conserved sequence motifs and the seven-pass 
transmembrane topology, and their function is to transmit information from the surroundings 
to the cellular interior 26. Extracellular stimuli transduced by GPCRs are diverse, ranging from 
physical stimuli, in the form of light, heat or mechanical force, to chemical stimuli with various 
compounds, such as peptides/proteins, sugars, lipids. It is therefore fair to say that GPCRs 
mediate and/or modulate virtually all physiological processes in eukaryotic organisms, 
including acute and chronic pain. 
GPCRs transduce external stimuli via two principal signaling pathways: (1) through the 
heterotrimeric G proteins, which was the first signal transduction pathway to be understood 
and to which GPCRs owe their name, or via (2) arrestins, initially described as proteins that 
turn off G protein signaling, since recruitment of arrestins, following the phosphorylation of 
GPCRs by GPCR kinases (GRKs), blocks GPCRs interaction with G proteins 27-31. 
Traditionally, it was assumed that GPCRs exist in two distinct conformations, active and 
inactive, and that the active GPCR conformation is the one that is preferred by both, G proteins 
and GRKs/arrestins – the classical extended ternary complex model of GPCR-driven signaling. 
However, structural studies by X-ray crystallography and cryo-electron microscopy (cryo-EM) 
and advanced Nuclear Magnetic Resonance (NMR) and Electron Paramagnetic Resonance 
(EPR) based techniques reveal that unliganded GPCRs exist in equilibrium between multiple 
conformations (basal equilibrium), which specific ligands partially shift towards different 
conformations 27-31. Now, while there are different active and inactive conformations, there is 
thus far no evidence that conformations preferred by G proteins and GRKs/arrestins are 
different. Thus, within the limitation of current techniques, the active GPCR conformation 
preferred by G proteins and GRKs/arrestins is one and the same 27-31 (Fig. 2). 
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Figure 2. Conformational heterogeneity of G protein-coupled receptors (GPCRs) and signaling. In untreated 
cells, unliganded GPCRs appear to exist in an equilibrium between multiple conformations, so-called basal 
equilibrium. Agonists shift this equilibrium towards active conformations. Antagonists have no effect on their 
own, but block agonists’ access to the receptor. The great majority of active conformations effectively couple to 
G proteins and GRKs/arrestins, but there are likely some that might preferentially engage distinct signal 
transducers (biased signaling). Image reproduced from reference 27: Gurevich and Gurevich, Int. J. Mol. Sci. 2017 
18(12): 2519 (permitted under the Creative Commons Attribution License).   
Receptor mediated signaling that arises due to spontaneous population of the active receptor 
conformations in the absence of a specific ligand is called constitutive activity. Agonist binding 
to a GPCR stabilizes the receptor in an active conformation that interacts with its cytoplasmic 
partner. When these partners are the heterotrimeric G proteins, ligand binding promotes the 
exchange of GTP for GDP from the Gα subunit. The GTP-bound Gα subunit dissociates from 
the Gβγ, and the GTP-liganded Gα and Gβγ separately stimulate various effector molecules 
thereby activating/inhibiting the production of a number of second messengers inside the cell, 
including the MAPKs such as ERK1/2 and p38 29-28. When agonist binding facilitates the 
phosphorylation of the C-terminal tail by GRKs, leading to the recruitment of arrestins, 
downstream signaling pathways distinct from those mediated by G proteins are being activated, 
such as endocytosis through interactions with the clathrin adaptor protein 2 (AP2) complex, 
but also common ones, such as ERK1/2 signaling.  
The existence of equilibrium between multiple active and inactive GPCR conformations in 
unstimulated cells, before they are being treated with specific ligands, is crucial for 
understanding the complexity underlying GPCR-ligand pharmacology. In line with this, the 
efficacy of a ligand is described with respect to the extent to which it can potentiate the 
signaling pathway that is dominant in unstimulated cells 27,30-32. Thus, agonists promote activity 
above the basal level through the dominating signaling pathway, i.e. they favor action through 
the active conformation of the receptor. Endogenous ligands are per definition full agonists. 
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Partial agonists also act on the active conformation but produce weaker maximal activity at 
saturation than full agonists. Inverse agonists lower the activity through the dominating 
signaling pathway below the basal state level recorded in untreated cells by favorably acting 
on the inactive conformation of the GPCR. Neutral antagonists do not affect the basal activity, 
but compete with agonists for the same ligand-binding site. Finally, some ligands can stimulate 
both G protein and arrestin pathways, or multiple G proteins, and the greater efficacy toward 
one or the other is known as ligand bias. The ability of some ligands to stimulate both pathways 
may be responsible for many of the undesired effects of drugs targeted to GPCRs 30.  
The equilibrium between the active and inactive conformations is dynamic and the 
residence time of GPCRs in the active/inactive conformations is, while receptor- and ligand-
specific, in the sub-millisecond to tens of milliseconds range 27-31. In addition, it is important 
to note that even at full signaling, only a portion of the receptors are occupied by the ligand. 
Thus, only a fraction of receptors are activated during a full signaling response, while the 
remaining receptors comprise the so-called receptor reserve 33.   
While numerous GPCRs are implicated in pain physiology, members of the opioid and 
the serotonin GPCR families are the ones that are of utmost relevance for pain 
pharmacotherapy.  
 
1.2.1 Opioids and opioid receptors  
The endogenous opioid system consists of four opioid receptor types: mu- (MOP), kappa- 
(KOP), delta- (DOP) and nociceptin (NOP), and their corresponding endogenous peptide 
ligands: endorphins, dynorphins, enkephalins and nociceptin/orphanin FQ, respectively.  
Opioid receptors and opioid peptides are widely expressed across the nervous system, and pain 
pathways in particular. They modulate the nervous system function at all levels of integration, 
including autonomic, sensory, emotional and cognitive processing. MOP, DOP and KOP 
facilitate spinal analgesia, with MOP also mediating supraspinal analgesia 34.  
At the cellular level, opioid receptors activate G protein dependent and independent signaling 
pathways. G protein dependent pathways involve both, signaling through the inhibitory Gi/Go 
subtypes of Gα and the Gβγ subunits, leading to the inhibition of cAMP, opening of K
+ and 
closing of Ca2+ channels. G protein-independent signaling cascades include arrestin-mediated 
activation of ERK1/2 and c-Jun N-Terminal Kinase 2. Moreover, activation of the p38 MAPK, 
protein kinases A and C, signal transducer and activator of transcription 3 (STAT3) and, 
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calmodulin-dependent protein kinase II (CAMKII) were also observed, but whether these 
pathways are dominantly activated via G proteins or arrestins is not clear  35-38. 
While all opioid receptors are implicated in the modulation of pain, deletion of the OPRM1 
gene has shown that MOP alone is responsible for both, the therapeutic and the adverse effects 
of morphine 39. MOP is also the target for other clinically useful opioids, such as fentanyl, 
codeine and oxycodone, which were studied here. We therefore focus on MOP only. 
As for other opioid receptors, intracellular effects of MOP activation are ligand-specific and 
include inhibition of adenylyl cyclase activity, closing of voltage gated Ca2+ channels, 
activation of inwardly rectifying K+ channels and stimulation of MAPK pathways 40,41. Post 
activation, MOPs are endocytosed and recycled back to the plasma membrane, through a 
pathway that includes phosphorylation by GPCR kinase and binding of arrestins. MOP 
endocytosis plays a key role in the occurrence of problematic side effects, from opioid 
treatment 41. A recent study, in mice, showed that analgesic tolerance and OIH, caused by 
opioid agonists, could be limited by co-treatment with MOP antagonist 42, while another study, 
in rats, showed that MOP antagonists restore the antinociceptive effects of morphine by 
suppressing the p38 MAPK signaling pathway 43. Additionally, chronic treatment with MOP 
antagonists was found to upregulate MOP in rats, but showed no increase in MOP mRNA 
levels, which suggested that MOP antagonists altered receptor compartmentalization, post 
translational modifications or turnover 36,44 
Opioids are among the most effective analgesics and play a key role in the descending anti-
nociceptive pathway 1. Exogenous opioids mimic endogenous opioid peptides in PAG, RVM 
and the spinal dorsal horn to induce analgesia 4. Immune cells synthesize and secrete 
endogenous opioid peptides like β-endorphin, Met-enkephalin and dynorphin, in response to 
stress stimuli causing secretion of the corticotropin-releasing factor or hormone 10. 
New tools and innovative approaches are revealing that opioid receptors are more complex 
than previously appreciated 13,45,46. They bring new insights into how opioid receptors signal 
and reveal the significance of receptor trafficking 47-49. For example, Erbs et al. showed in 
knock-in mice that interactions between MOP and DOP could be either at system-level or 
heteromerization, depending on the region of the brain 47.    
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1.2.2 Serotonin and Serotonin receptors  
In mammals, 5-HT works as a neurotransmitter in the central and peripheral nervous system. 
The RVM includes, among other structures, the serotonin-rich NRM 4. 5-HT is associated with 
a multitude of physiological and pathological processes, including functioning as a local 
hormone in some tissues. The serotonin receptor 1A (5-HT1A) is part of the 5-HT1 family, 
which also includes 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F. Like the opioid receptors, this 
receptor family couples to Gi/o, which inhibit adenylyl cyclase and lowers cAMP levels. 
Activation of 5-HT1A also activates the ERK1/2 MAPK signaling pathway, although this is 
believed not to be a universal response in the brain 50. 5-HT1A has a wide distribution in the 
CNS 51,52. It is also found in dendrites, the soma and sometimes in the axon hillock of neurons. 
All serotonin neurons express 5-HT1A, as do many nonserotonergic neurons. Activation of 5-
HT1A has a general inhibitory electrophysiological effect, manifested in reduced neuronal firing 
rates. Several neuropsychiatric disorders are thought to have a 5-HT1A pathway which, 
consequently, has made 5-HT1A a therapeutic target. Clinically used ligands include partial 
agonists, neutral antagonists 12 and full agonists (the drug buspirone acts as a full agonist on 
presynaptic 5-HT1A and as a partial agonist on postsynaptic 5-HT1A) 
53,54. Buspirone was first 
introduced as an anxiolytic in 1986 55,56. It belongs to the class of drugs referred to as 
azapirones, of which there are currently two approved drugs (buspirone and tandospirone) 57. 
Since its introduction, studies on buspirone have included combinatory/augmentation strategies 
for depression, immune system modulation in HIV, ethanol consumption and morphine 
tolerance, to name but a few 58-61. Augmentation of morphine treatment with buspirone was 
found to elicit a better pain control response and helped to hamper the development of tolerance 
in animals 61. 
 
1.2.3 MOP and 5-HT1A receptor interactions  
GPCR homo- and heterodimerization is an important mechanism through which cellular 
signaling repertoire can be expanded without the need for designing new biological molecules. 
Many GPCRs form functional homo- and heterodimers, and so does MOP, as documented in 
numerous studies recently reviewed by Massotte 62. However, heterodimer formation between 
MOP and 5-HT1A was thus far documented in one study only 
41, even though numerous studies 
reveal the co-expression and co-localization of MOP and the 5-HT1A in discrete areas of the 
brain, such as PAG neurons, dorsal raphe nucleus, dorsal horn of the spinal cord, amygdala and 
primary afferent nociceptive fibers, suggesting that these receptors function in close adjacency 
to one and other. Although the interactions between opioid and serotonergic signaling are not 
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fully understood 1,63, the cAMP pathway is known to crosstalk with the MAPK pathway, with 
key interactions involving ERK1/2 and p38 64. Furthermore, genetic studies indicate an 
interaction between 5-HT1A and MOP signaling on the function of endogenous descending pain 
inhibition in healthy subjects and pain patients 65 as well as an effect of serotonergic signaling 
on opioid induced analgesia in healthy subjects 66. The 5-HT1A receptor is an inhibitory 
presynaptic autoreceptor on serotonergic neurons and is also expressed postsynaptically in 
terminal regions innervated by serotonergic neurons 67. The 5-HT1A and MOP receptors co-
localize on individual presynaptic GABAergic nerve terminals and have been demonstrated to 
synergistically inhibit GABA release in PAG, thus likely affecting analgesia 41. Through 
behavioral studies, on morphine addiction and tolerance, a hypothesis of cooperation between 
MOP and 5-HT1A has been suggested 
41. In animal studies, 5-HT1A receptor agonists have been 
reported to counteract opioid-induced hyperalgesia, opioid tolerance and to improve the 
analgesic potential of opioids while reducing their rewarding effects 63,68,69. This strategy is 
believed to engage serotonergic input from the raphe nuclei to the ventrolateral PAG. 
Serotonin, in addition, also regulates the opioid-induced descending antinociceptive pathway 
41. Contrary to opioids, a first order pronociceptive effect followed by a second order analgesic 
effect has been documented for 5-HT1A agonists, suggesting opposing effects between opioids 
and 5-HT1A agonists 
68. Therefore, hypothetically, 5-HT1A/MOP interactions could be time-
dependent with 5-HT1A antagonists initially enhancing opioid analgesia 
70,71 while 5-HT1A 
agonists would have beneficial long-term effects, when OIH has presented 63,68,69. In clinical 
settings, serotonin selective reuptake inhibitors (SSRIs) have not been found to have an 
analgesic effect on patients. However, analgesic effects have been shown by tricyclic 
antidepressants and serotonin- and noradrenalin reuptake inhibitors (SNRI) 72. In addition, 
MOP have been shown to modulate the effects of 5-HT1A agonists in rats 
73. Furthermore, a 
study of HEK 293 cells demonstrated formation of functional MOP/5-HT1A heterodimers and 
that signaling of one receptor in the MOP/5-HT1A heterodimer was inhibited by activation of 
the other receptor, i.e., pretreatment with a 5-HT1A agonist abolished subsequent ERK1/2 
activation by a MOP agonist 41.  
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2 AIM 
Based on inferences made from clinical studies by Kosek et al. 66, it was hypothesized that 
heterodimer formation between MOP and 5-HT1A receptors may underlie the development of 
OIH. The primary aim of my work was to challenge the hypothesis that prolonged exposure to 
non-peptide opioids promotes heterodimer formation between MOP and 5-HT1A receptors, and 
that this effect can be abolished by co-treatment with 5-HT1A agonists. To this overall aim: 
 The first objective of my work was to use molecular cloning to develop cell lines of 
human and rat origin that stably express physiologically relevant levels of MOP and 5-
HT1A receptors tagged with spectrally distinct fluorescence reporters.  
 The second objective of my work was to use advanced fluorescence microscopy 
imaging and correlation spectroscopy techniques to quantitatively characterize in live 
cells interactions between MOP and 5-HT1A receptors and to characterize the 
consequences of agonist exposure on intracellular signaling.  
 The third objective of my work was to characterize the effect of selected non-peptide 
opioids on the extent of MOP and 5-HT1A heterodimerization. 
 The fourth objective of my work was to investigate wether non-peptide opioid-induced 
MOP and 5-HT1A heterodimerization can be abolished by co-treatment with 5-HT1A 
agonists. 
In Paper I, we showed that prolonged exposure to non-peptide opioids facilitated heterodimer 
formation between MOP and 5-HT1A receptors in live cells expressing physiologically relevant 
receptor levels. The extent of receptor heterodimerization was found to be both, opioid-specific 
and dose-dependent. Furthermore, we showed that different opioids differently affected second 
messenger pathways, as indicated by differences in Ca2+ signaling dynamics and differential 
activation of p38 and ERK1/2 pathways.  
In Paper II, we showed that 5-HT1A agonists such as buspirone and three newly identified 
buspirone analogs: B2, B3 and B5, can effectively reverse MOP–5-HT1A heterodimerization, 
thus counteracting the aversive effects of morphine. Importantly, this study, which brought 
together molecular modeling, virtual screening and advanced experimental tests in live cells, 
may in the future lead to the development of new drugs that target MOP and 5-HT1A 
heterodimer formation.  
In paper III, we have quantitatively characterized using FCS/FCCS and PhotoActivated 
Localization Microscopy (PALM) the nanoscale lateral dynamics and spatial organization of 
wild type MOP and its naturally occurring isoform MOPN40D, and showed that these properties 
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important determinants of opioid receptors’ function. In particular, we found MOP to be largely 
excluded from GM1 ganglioside-enriched domains and associate with cholesterol and GPI-
enriched domains. We demonstrated that these properties can be altered under the influence of 
exogenous substances, such as drugs, but may also be altered in disease conditions, leading to 
altered kinetics of ligand-receptor interactions and the receptor-mediated signaling dynamics. 
We also showed that MOP and MOPN40D differ with respect to nanoscale lateral dynamics and 
organization, which may, at least in part, explain why carriers of the MOPN40D isoform differ 
with respect to their response to pain, analgesics and substances of abuse.   
In addition, an important objective of my PhD training, was to implement advanced 
fluorescence microscopy and correlation spectroscopy-based analytical techniques for the 
study of molecular mechanisms that underlie cellular uptake. Papers IV and V describe 
collaborative work where CLSM and/or FCS/FCCS were used to characterize translocation 
across the plasma membrane and cellular uptake of biomolecules. 
In Paper IV, FCS/FCCS was used to reveal the heterogeneity underlying self-assembly of cell-
penetrating peptides and oligonucleotides, in this case small interfering RNA (siRNA), into 
large molecular complexes. We showed that peptide monomers, peptide self-aggregates and 
polydisperse peptide/cargo complexes coexist in solution and in live cell plasma membrane, 
which could at least in part explain why diverse cellular uptake mechanisms were 
simultaneously observed for cell-penetrating peptides-based delivery of cargo molecules.  
In Paper V, cellular and molecular mechanisms underlying the development of allergy to red 
meat were investigated, with a particular focus on the role of α-Gal carbohydrate on protein 
uptake and degradation by immature monocyte-derived dendritic cells (iMDDCs). CLSM 
imaging revealed that presence of allergenic α-Gal epitopes on the protein surface significantly 
increases the uptake of the investigated model antigens, BSA-α-Gal and HSA-α-Gal, by in vitro 
cultured human iMDDCs, and showed that the taken up proteins are processed in endosomes. 
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3 RESEARCH APPROACH 
The main technique utilized in this thesis to quantitatively characterize the interactions between 
MOP and 5-HT1A receptors is Fluorescence Cross-Correlation Spectroscopy (FCCS). FCCS is 
a non-destructive, highly sensitive and inherently quantitative technique that is well suited for 
studies of molecular interactions in live cells because it can identify bound molecules as they 
move together and quantitatively characterizes their concentration without having to separate 
the free and bound fractions 55. FCCS is more versatile and better suited for such studies than 
the Förster Resonance Energy Transfer (FRET) assay that is commonly used 74. While for 
efficient non-radiative energy transfer to occur the molecules need to be very close to one 
another, at distances shorter than 10 nm, the fact that two molecules are in the vicinity of one 
another does not necessarily mean that they interact. Thus, FRET is a proximity assay, rather 
than a true binding assay. Moreover, FRET efficiency is hampered by false negative results 
due to steric hindrances – for resonance energy transfer to occur, efficient dipole–dipole 
coupling between the fluorophores that constitute the donor-acceptor pair needs to be achieved. 
This, in turn, means that resonance energy transfer will only take place in a small population 
of properly oriented molecules. Such requirement does not exist in FCCS.     
In addition to FCCS, complementary fluorescence techniques as well as classical biochemical 
assays were utilized to thoroughly explore the consequences of the molecular interactions and 
cellular responses described in the introduction.  The research approach section includes an 
introduction to FCCS, fluorescence correlation spectroscopy (FCS) as well as confocal laser 
scanning microscopy (CLSM). The author also presents selected protocols applied throughout 
the five research papers and statistical analysis. Additional methods and methods contributed 
by co-authors are described in detail in the research papers included in this thesis. 
 
3.1 THEORY OF FCS AND FCCS 
Since its inception, almost 50 years ago, Fluorescence Correlation Spectroscopy (FCS) has 
developed from an abstruse measurement technique to a widely utilized research tool that is of 
particular value for nondestructive quantitative analysis in live biological specimen 75. This 
quantitative technique with high temporal (sub-microsecond) and spatial (sub-micrometer) 
resolution and the ultimate, single-molecule sensitivity, relies on the analysis of fluorescence 
intensity fluctuations around an average value (equilibrium or non-equilibrium stationary state) 
to extract quantitative information about the concentration and diffusion of fluorescent 
molecules, when the fluorescence intensity fluctuations are generated by molecular diffusion, 
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and/or the kinetics of a blinking process, when the fluctuations are generated by molecules 
alternating between dark and bright states 76,77. FCS acquired its ultimate sensitivity and real-
time analysis feature when it was realized that the arrangement of optical elements that is 
employed in confocal microscopes can be utilized to generate a minute observation volume 
element (OVE) in the sample. The volume is nowadays typically 0.1 – 2 fl (0.1 – 2×10-15 l). 
This reduction in OVE size that was achieved by integrating FCS with confocal microscopy, 
significantly decreased the background from surrounding molecules, markedly improving the 
signal-to-noise ratio and, thus, FCS sensitivity 26,75,76.  
Fluctuations in fluorescence intensity are typically evaluated using temporal autocorrelation 
analyzis. For nonrandom fluctuations, temporal autocorrelation analysis of the fluorescence 
intensity fluctuations generates a decaying temporal autocorrelation curve (tACC), where the 
amplitude at the zero-lag time is inversely proportional to the average number of molecules in 
the OVE and the characteristic decay time contains information about the diffusion of  
molecules 78-80 75,78,80-84. Briefly, a time-dependent fluctuation in fluorescence intensity is 
expressed as a fluorescence signal at time t, F(t), measured against the time-averaged signal 
⟨F(t)⟩ 78,80. 
𝛿𝐹(𝑡) = 𝐹(𝑡) − 〈𝐹(𝑡)〉      (1) 
and the normalized autocorrelation curve is calculated as: 
𝐺(𝜏) = 1 +
(𝛿𝐹(𝑡)𝛿𝐹(𝑡+𝜏))
〈𝐹(𝑡)〉2
 ,     (2) 
where the fluorescence intensity fluctuation trace is compared to a “shifted” version of itself. 
The “shift”, called the lag time, 𝜏, is varied to identify whether there is a characteristic value of 
𝜏 after which the correlation is being lost 76,80. 
The average time a fluorescent molecule resides in the OVE, the so-called residence time, or 
the average time that it takes a molecule to “cross” the OVE by translational diffusion, called 
the translational diffusion time, is designated τD. 𝜏D is directly related to the size of the OVE 
and the diffusion coefficient (D) of the molecule: 
𝜏𝐷 =
𝑤𝑥𝑦
2
4𝐷
 ,      (3) 
where 𝜔𝑥𝑦
2  is the radial radius of the OVE squared.   
Molecular diffusion at the plasma membrane is two-dimensional (2D), and is often called 
lateral diffusion. To extract from the tACC quantitative information about the average number 
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of molecules in the OVE (N) and the lateral diffusion time (𝜏D), the experimentally determined 
tACC is fitted with a theoretically derived equation for 2D-diffusion 76:  
𝐺𝑑𝑖𝑓𝑓(𝜏) =
1
𝑁
(1 +
𝜏
𝜏𝐷
)
−1
 .    (4) 
The study of interactions between molecules of similar size can be problematic in FCS, as a 
two-fold change in size will result in a change in diffusion time that is proportional to the cubic 
root of two. A more suitable technique for characterizing interactions between molecules of 
similar size is Fluorescence Cross-Correlation Spectroscopy (FCCS) 80,85. In FCCS, 
fluorescence intensity fluctuations from two spectrally distinct fluorophores are collected and 
analyzed, both in regards to their self-similarity (autocorrelation) and interaction (cross-
correlation). Cross-correlation is a “measure” of the number of fluorescence intensity 
fluctuations detected simultaneously in two channels, which corresponds to two spectrally 
distinct molecules that are co-diffusing 78. This analysis generates two tACCs and one temporal 
cross-correlation curve (tCCC).  
For biological applications, fluorescent proteins which emit fluorescence in the green and red 
part of the spectrum are a common pair. We will therefore generally denote them as r (red) and 
g (green). In FCCS, the two tACC reflect the total number of green and red labeled molecules 
respectively, and Ng
total = Ng + Ngr and Nr
total = Nr + Ngr. Assuming ideal conditions, (same 
effective volume element and fully separated absorption/emission spectra) the cross-correlation 
function can be described as 80,86: 
𝐺𝐶𝐶(𝜏) = 1 +
〈𝛿𝐹𝑔𝑟𝑒𝑒𝑛(𝑡)∙𝛿𝐹𝑟𝑒𝑑(𝑡+𝜏)〉
〈𝐹𝑔𝑟𝑒𝑒𝑛(𝑡)〉〈𝐹𝑟𝑒𝑑(𝑡)〉
    (5) 
 
The zero-lag time amplitude of the tCCC is directly proportional to the number of dually 
labeled co-diffusing molecules. Which means that as Ngr increases so does the amplitude of the 
tCCC: 
 𝐺𝐶𝐶(0) − 1 ∝
𝑁𝑔𝑟
(𝑁𝑔+𝑁𝑔𝑟)∙(𝑁𝑟+𝑁𝑔𝑟)
    (6) 
In order to calculate the contribution of dually labeled fluorescent molecules, the values at zero-
lag time for both tACCs and the tCCC can be determined, and post-processed mathematically 
to generate a dimensionless value known as the relative cross-correlation amplitude (RCCA): 
𝑅𝐶𝐶𝐴 =
𝐺𝑐𝑐(𝜏)−1
𝐺𝐴𝐶(𝜏)−1
=
𝑁𝑔𝑟
𝑁𝑟
𝑡𝑜𝑡𝑎𝑙 =
𝑁𝑔𝑟
𝑁𝑟+𝑁𝑔𝑟
     (7) 
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This analysis gives the number of double-labeled, i.e. heterodimer receptor complexes (Ngr) 
relative to the total number of the red labeled (Nr
total), including the single-labeled (Nr) and the 
double-labeled (Ngr) ones 
26,85. 
 Strictly speaking, equations (6) and (7) are valid under the assumptions that fluorophore 
brightness is not changing upon binding and that there is no spectral cross-talk between the 
channels. The contribution due to spectral cross-talk can be corrected following procedures 
described in 23, 90 and 87. Briefly, the cross-talk-induced cross-correlation needs to be subtracted 
from the relative cross-correlation and the remaining cross-correlation scaled up as follows: 
 𝑅𝐶𝐶𝐴𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =
RCCA − κ∙𝑓
1 − κ∙𝑓
 ,    (8) 
where  is the bleed-through ratio, i.e. brightness as reflected by the counts per second and per 
molecule (CPM) of the green dye in the red channel when the red fluorophore is not present, 
divided by its brightness in the green channel. For the optical setting used in our studies,  = 
0.1, and f is the count rate ratio in the green and red channels, f = CRg/CRr  0.5. Following 
treatment, increase in eGFP brightness was observed, while Tomato brightness remained 
largely unchanged. To account for this, the  factor was accordingly scaled, becoming, at most 
 = 0.2, and the product f  0.15. 
 
3.2 CONFOCAL LASER SCANNING MICROSCOPY  
A confocal laser scanning microscope utilizes a specific arrangement of optical elements and 
spatial filtering of the fluorescence signal by pinholes to improve the signal-to-background 
ratio by excluding out-of-focus light 88. CLSM utilizes point-by-point illumination of the 
sample and fluorescence detection. This has the drawback that few emitted photons reach the 
detector. This requires the sample to be illuminated for a longer time, so that each point gets 
sufficiently illuminated thus avoiding noisy images 88,89.  
Spatial resolution of a CLSM system depends on the numerical aperture (NA) of the objective 
lens, a dimensionless value that characterizes the light-gathering ability of the lens according 
to the formula:  
NA = n∙sin ,     (9)
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where n is the index of refraction of the medium in which the lens is working (nair = 1.00, nwater 
= 1.33 and noil =  1.52 (for typically used immersion oils)) and  is the maximal half-angle of 
the cone of light that can enter or exit the lens.  
The numerical aperture and the wavelength of incident light (), are the main determinants of 
the size of the Airy pattern, a bright circular region in the center, known as the Airy disk, 
surrounded by concentric bright and dark rings that are formed by constructive and destructive 
interference, respectively, of diffracted light after passing  through a lens with a circular 
aperture). The center of the Airy pattern (out to the first minimum) is referred to as the Airy 
disk and contains approximately 86 % of the total light. The Rayleigh criterion stipulates that 
the minimum distance between two Airy disks, for which they are distinguishable, is equal to 
their radii 89. From the Airy pattern a point spread function (PSF) can be calculated. The full 
width at half maximum (FWHM) of the PSF gives an indication of the optical resolution of the 
microscope (Fig. 3). 
 
Figure 3. Appearance of two point sources separated by 150 nm via current commercially available 
diffraction-limited and super-resolution microscopes. A) Overlapping PSFs (approximated by Gaussians) 
typical of Confocal Laser Scanning Microscopy (CLSM). B) Structured Illumination Microscopy (SIM). C) Single 
Molecule Localization Microscopy (SMLM).  D) Stimulated Emission Depletion (STED). The PSF cartoons to 
the right represent the effective precision associated with each method. Image reproduced from reference XX: 
Brian R Long, Danielle C Robinson and Haining Zhong. Subdiffractive microscopy: techniques, applications, and 
challenges. Wiley Interdiscip Rev Syst Biol Med. 2014 6(2): 151–168, with permission from the Publisher.   
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In the focal plane, radial direction (x and y plane), the spatial resolution limit is: 
 
𝑑𝑥𝑦 = 𝑃𝑆𝐹𝐹𝑊𝐻𝑀 ≈ 0.61𝜆0/𝑁𝐴    (10) 
 
and in the axial direction (z-axis):  
  
𝑑𝑧 ≈ 𝑛𝜆0/𝑁𝐴
2     (11) 
 
where λ0 is the excitation wavelength and n the refractive index of the medium. High NA 
objectives can generate PSFFWHM that is about 200-250 nm wide radially in the focal plane and 
500-700 nm in the optical axis. Although noteworthy, this resolution cannot confidently resolve 
structures that are smaller/objects that are closer than 200 nm, which remains a challenge for 
many applications in life sciences (Fig. 3A) 13. The limitation in spatial resolution due to 
diffraction of light, which is known as the diffraction limited spatial resolution, is circumvented 
in super-resolution fluorescence microscopy techniques 90,91. There are three principally 
different ways how this can be achieved. Briefly, in Structured Illumination Microscopy 
(SIM)92,93, a high NA objective (NA = 1.7) and a movable diffraction grating placed in the path 
of the laser beam are used to illuminate the sample in a stripe pattern generated by interference, 
for which the minimum stripe distance is close to the resolution limit. To achieve high spatial 
resolution in all directions, a series of raw images is consecutively acquired with translationally 
phase-shifted and rotated illumination. The information is then retrieved through mathematical 
reconstruction and a contrast-enhanced image with a two-fold increased lateral and axial 
resolution is obtained (Fig. 3B). However, due to errors in grating position, system calibration, 
refractive index mismatch, sample heterogeneity and poor quality artifacts in a SIM image can 
be introduced that are difficult to recognize and remove. Also, SIM is slow, requiring 1 – 30 s 
processing time, which may be too slow for the study of fast processes. 
Like SIM, Single-Molecule Localization Microscopy (SMLM) is a wide field imaging 
technique that includes methods such as PhotoActivated Localization Microscopy (PALM) and 
Stochastic Optical Reconstruction Microscopy (STORM). In SMLM, a small subsets of 
individual molecules are randomly activated or switched on/off in consecutive acquisitions. If 
sparse enough, single-molecule switching events are identified. By collecting the signal over 
several thousands of camera frames, the signals become spatiotemporally separated. Raw data 
are thereafter processed to detect single molecules and determine their centers of positions. The 
precision with which the centers of position of an individual molecule can be determined 
depends on the number of photons detected per individual molecule. In SMLM, the standard 
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error of the mean of the PSF, which is a measure of the localization precision, can be made 
arbitrarily small by collecting more photons and by minimizing the noise factors 94,95: 
𝜎 =  √
𝑠2
𝑁
+
𝑎2
12𝑁
+  
8𝜋𝑠4𝑏2
𝑎2𝑁2
  ,     (12) 
where s is the standard deviation of the Gaussian distribution that equals 1/2.2 of the PSF width, 
a is the pixel size,  b is the background and N is the number of collected photons. Thus, by 
collecting a sufficient number of photons, N = 10 000, the errors due to: the photon noise (first 
term in eq. (12)), finite pixel size of the detector (second term in eq. (12)), error due to the 
effect of the background (third term in eq. (12)), all become very small and individual 
molecules can be localized with a nm precision. Finally, all localizations of individual 
molecules with their corresponding localization precision are then assembled through 
superimposition into a single-plane super-resolution SMLM image (Fig. 3C). Like SIM, 
SMLM is slow and requires computational post-processing. It therefore cannot be easily used 
to study fast dynamic processes. An additional limitation originates from the high number of 
emitted photons that are required to achieve a sufficient signal-to-noise ratio. The number of 
photons that need to be collected is proportional to the number of pixels in the image, and 
increases in proportion to the square (for 2D) or the cube (for 3D) imaging. 
In STED microscopy 96, a depletion laser beam with a local intensity minimum in the 
center is superimposed on the confocal excitation beam. The depletion laser forces molecules 
excited by the confocal excitation laser to undergo stimulated, rather than spontaneous de-
excitation, thus effectively preventing fluorescence emission from other locations than the local 
intensity minimum. Efficient restriction of spontaneous fluorescence emission to the central 
region enables imaging of sub-diffraction scales (Fig. 3D). Unlike SIM and SMLM, which are 
wide-field techniques, STED is a scanning technique, which means that there is a time delay 
across the image. On the positive side, this means that computational post-processing is not 
necessary, although deconvolution is often applied to compensate for low signal in samples 
with increased background. Like SMLM and SIM, STED is not well suited for the study of fast 
dynamical processes. Also, STED is not quantitative, if not coupled with FCS 97. Finally, the 
most serious limitation of STED microscopy for applications in biomedical research is high 
photobleaching and high photo-toxicity. 
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3.3 CELL MODEL 
The most common strategy for live cell fluorescence experiments is to genetically modify cells 
to stably express recombinant proteins, i.e. proteins of interest coupled to fluorescent 
proteins98,99. This strategy can be applied to commercially available immortalized mammalian 
cell lines 100. One of the most commonly used mammalian cell line for expressing recombinant 
proteins is the human embryonic kidney cell line (HEK 293) 100,101. Despite having an epithelial 
origin, HEK 293 cells are capable of most post translational folding and modifications required 
to produce mammalian proteins. HEK 293 cells are viewed as a good system when evaluating 
pharmacological properties 101. The rat phaeochromocytoma (PC12) cell line is a popular 
mammalian cell line owing to its versatility for pharmacological manipulation 102.  
Both HEK 293 and PC12 cells can be transfected to stably express recombinant proteins 
via the method of lipofection 101,103,104. By using a mammalian dual expression vector 
(pBudCE4.1), with two strong promoters (CMV and hEF-1) 100, both HEK 293 and PC12 cells 
can be transfected to express MOP and 5-HT1A, coupled to spectrally distinct fluorescence 
proteins. Conventionally green and red shifted fluorescent proteins (FP) are used. Among the 
red shifted FP a common family is the “mFruit” family (m stands for monomeric). This class 
of FP showcase a wide range of red shifted colors, however, most mFruit FP suffer from low 
intrinsic brightness and poor photostability. The dimeric red shifted FP Tomato, is a derivative 
of the mFruits, that has better brightness and photostability than its monomeric counterparts 84. 
  
3.4 PROTOCOLS 
3.4.1 Cell culturing 
Both HEK 293 and PC12 cells were cultured in collagen-coated T25 flasks (SARSTEDT). 
HEK 293 cells where grown in DMEM medium supplemented with 10 % fetal bovine serum 
(FBS) and PC12 cells in RPMI 1640 medium supplemented with 10 horse serum (HS) and 5 
% FBS. Both growth media were supplemented with 100 U / mL penicillin and 100 μg / mL 
streptomycin (PenStrep) (all from Invitrogen, Sweden). Both cell lines were cultured at 37°C 
in a humidified 5 % CO2 incubator.  
3.4.2 Cell transfection  
Both HEK 293 and PC12 cells were seeded in eight-well Nunc™ Lab-Tek™ Chambered 
Coverglass with 1.0 borosilicate bottom (Thermo Scientific) to a total volume of 300 µl per 
well. Cells were transfected with Lipofectamine 2000 (Invitrogen, Sweden), using the 
manufacturer’s transfection protocol (for an eight-well system: 400 ng of DNA and 2.5 µl of 
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Lipofectamine 2000). For both cell lines the growth medium was changed to Opti-MEM 
(Invitrogen, Sweden) during the transfection.  
For dual expression experiments the cells were transfected with pBudCE4.1 plasmid, which 
can express two genes simultaneously via CMV and hEF-1 promoters. MOP fused with 
enhanced green fluorescent protein (eGFP) is expressed under control of hEF-1 promotor 
(KpnXho) and 5-HT1A fused with the red fluorescent protein dimeric tomato red (Tomato), 
under control of CMV promoter (HindXba) 100. Stably expressing cells (Fig.  4) were isolated 
through selection with phleomycin D1 antibiotic (0.4 mg/ml, ThermoFisher). 
3.4.3 CLSM imaging 
The CLSM/FCCS measurements were carried out on an in-house ConfoCor3 (Carl Zeiss, Jena, 
Germany), with unique modifications. The system comprises an inverted microscope for 
transmitted and epifluorescent (Axiovert 200 M) light; a VIS-laser module housing an Ar/ArKr 
laser (458, 477, 488 and 514 nm), a HeNe (543 nm) laser and a HeNe (633 nm) laser; scanning 
module LSM 510 META modified to enable imaging with silicon avalanche photodiodes 
(SPCM-AQR-1X, PerkinElmer, USA) and a FCS module with three detection channels (Figure 
1A). In all experiments with live cells a C-Apochromat 40× /1.2 W UV-VIS-IR objective (Zeiss 
MicroImaging GmbH, Jena, Germany) was used (papers I-IV). For imaging of fixed samples 
an alpha Plan-Fluar 100×/1.45 oil immersion objective (Zeiss MicroImaging GmbH, Jena, 
Germany) was used (paper V).  
CLSM images were acquired in a sequential, i.e., dual track mode, one channel at a 
time. eGFP fluorescence was excited using the 488 nm line of the Ar/ArKr laser. A band pass 
505-530 nm emission filter was used to spectrally narrow the emitted fluorescence. Tomato 
fluorescence was excited using the 543 nm HeNe laser, and a long pass 580 nm emission 
filter was used to collect the emitted fluorescence. Incident and emitted light were separated 
using the main dichroic beam splitter HFT 488/543/633. eGFP and Tomato fluorescence were 
separated using a secondary dichroic beam splitter NFT 545 (Fig. 4A). Images were acquired 
without averaging, using a pixel dwell time of 51.2 µs and a 512×512 pixels format (Fig. 4B).  
For live cell imaging an incubation stage was used, consisting of heated microscope 
stage (Heating insert P), incubator box (Incubator S), atmosphere-controller (CTI-Controller 
3700, supplying cells with heated mixture of CO2 and air) fitted with a humidifier and a 
temperature regulator (Temp control 37-2 digital). The temperature and CO2 levels were 
continuously monitored and regulated via a digital feedback control algorithm, allowing for 
optimal control of all parameters.  
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3.4.4 FCS / FCCS measurements on the plasma membrane 
For experiments on the plasma membrane, an axial z-scan was first performed, with a step 
length of 0.5 µm (papers I-IV). The scan generates a graph with two distinct peaks, which 
reveal the position of the basal and the apical plasma membrane (Fig. 4C). Fluorescence 
intensity fluctuations were recorded in arrays of 10 consecutive 10 s measurements when a 
single wavelength was used (FCS), and 20 s measurements when two wavelengths were used 
(FCCS) (Fig. 4D). The same optical setup was used for FCS/FCCS as for CLSM imaging.  
 
Figure 4. FCCS measurement in live cells. A) Schematic representation of the optical setup in an inverted 
epifluorescence confocal microscope for dual color imaging and FCCS. Incident light from two lasers, 488 nm 
(blue) and 543 nm (green) are merged and reflected by the main dichroic beam splitter (MDBS) and focused 
sharply onto sample. Both incident (blue and green) and the spectrally distinct fluorescent light (green and red) 
scatter elastically and are collected by the objective and separated by the MDBS. The emitted fluorescent light is 
further spectrally narrowed using a secondary dichroic beam splitter (SDBS) and matching emission filters (EF), 
before being recorded by Avalanche Photo Detectors (APD) detectors. B) CLSM images of HEK 293 (above) and 
PC12 (bellow) cells stably transformed to express MOP-eGFP (green) and 5-HT1A-Tomato (red). Scale bar 10 
µm. C) Fluorescence intensity scan the axial direction through a HEK 293 cell expressing MOP-eGFP (green) and 
5-HT1A-Tomato (red). The scan has two distinct peaks corresponding to the basal (firs) and apical (second) plasma 
membrane. D) Fluorescence intensity fluctuations recorded at the apical plasma membrane of a HEK 293 cell 
stably transformed to express MOP-eGFP (green) and 5-HT1A-Tomato (red). E) Corresponding temporal 
autocorrelation curves (green and red) and the cross-correlation curve (black) from D. The cross-correlation curve 
corresponds to the simultaneous passage of MOP-eGFP and 5-HT1A-Tomato through the OVE. 
The fluctuations in fluorescence intensity were analyzed using temporal autocorrelation 
analysis, yielding two distinct temporal autocorrelation curves (tACC), one for each 
monomeric species (Fig. 4E, green and red) and one temporal cross-correlation curve (tCCC) 
for the dimeric species (black) (Fig. 4E). Contrary to the amplitude of the tACC, which is 
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inversely proportional to the average number of molecules (N) in the OVE (eq. (4)), the cross-
correlation curve amplitude is directly proportional to the number of dually labeled molecules. 
3.4.5 Western blot 
The transgenic HEK 293 cells expressing MOP-eGFP and 5-HT1A-Tomato were cultured in 
collagen-coated T25 flasks in DMEM medium supplemented with 10 % FBS, PenStrep and 
0.4 mg / ml phleomycin D1 antibiotic. Upon reaching 90 % confluence the cell media was 
exchanged for media supplemented with agonist to MOP (paper I) or agonists to MOP and/or 
5-HT1A (paper 2). After 18 h incubation the adherent cells were removed from the flasks with 
trypsin-EDTA (0.05 %, Thermo Scientific), washed with ice cold PBS and centrifuged at 1500 
rpm for 5 min at 4 °C. The cell pellets were solubilized in RIPA lysate buffer (10x106 cells / 
ml, Sigma-Aldrich) containing protease inhibitor and phosphatase inhibitor (Sigma-Aldrich) 
and incubated for 30 min on ice. The cell solution was transferred to Eppendorf tubes and 
centrifuged at 10 000 rpm for 10 minutes. Total protein concentration was established for every 
sample with a colorimetric essay from BioRad RC DC Protein Assay (Bio-Rad). 20 µg of 
protein from each treatment was diluted to 30 µl with mili-Q water and denatured at 70 °C for 
10 min with 4X LDS Sample Buffer, 10X Sample Reducing Agent (Invitrogen). Samples were 
loaded on precast polyacrylamide gels (Invitrogen) along with 5 µl pre-stained protein ladder 
(Thermo Scientific), electrophoresed and transferred onto a nitrocellulose membrane (Thermo 
Scientific). The membrane was probed over night with mouse α-ERK1/2, rabbit α-Phospho-
ERK1/2, mouse α-β-actin (Invitrogen), mouse α-p38 and mouse α-Phospho-p38 
(CellSignaling). Only one primary antibody was used at a time and the membrane was stripped 
for 15 min with Western blot stripping buffer (Thermo Scientific) in-between the different 
primary antibodies. Depending on type of primary antibody, either biotin or horseradish 
peroxidase conjugated secondary antibody (Invitrogen) was used for detection. 
3.5 DATA REPRESENTATION AND STATISTICAL ANALYSIS 
Student's t-test was used to determine whether the difference between the mean values 
measured are significantly different from each other. The results are reported using a two-tailed 
P-value (P). P = 0.05 is used as the cutoff for significance. Calculations were performed in 
OriginPro 2018 (OriginLab Corporation, USA). Graphs and figures were generated using 
OriginPro 2018 and Adobe Photoshop CC (Adobe Systems Incorporated, USA) 
3.6 CALCULATING THE APPARENT DISSOCIATION CONSTANT 
The apparent dissociation constant for MOP-eGFP and 5-HT1A-Tomato binding can be 
derived as follows: 
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𝐾𝑑 =  
[𝑀𝑂𝑃−𝑒𝐺𝐹𝑃]𝑓𝑟𝑒𝑒∙[5−𝐻𝑇1𝐴−𝑇𝑜𝑚𝑎𝑡𝑜]𝑓𝑟𝑒𝑒
[𝑀𝑂𝑃−𝑒𝐺𝐹𝑃−5−𝐻𝑇1𝐴]
 ,                (13) 
where [MOP-eGFH]free and [5-HT1A-Tomato]free are concentrations of free receptors, MOP-
eGFP and 5-HT1A-Tomato, respectively, and [MOP-eGFP–5-HT1A-Tomato] is the 
concentration of receptor-receptor complexes. 
For both receptors, MOP-eGFP and 5-HT1A-Tomato, the concentration of free receptor 
molecules can be expressed as the difference between the total concentration and the 
concentration of receptor-receptor complexes, rendering equation (6a) into: 
𝐾𝑑 =  
([𝑀𝑂𝑃−𝑒𝐺𝐹𝑃]𝑡𝑜𝑡𝑎𝑙− [𝑀𝑂𝑃−𝑒𝐺𝐹𝑃−5−𝐻𝑇1𝐴])∙([5−𝐻𝑇1𝐴−𝑇𝑜𝑚𝑎𝑡𝑜]𝑡𝑜𝑡𝑎𝑙− [𝑀𝑂𝑃−𝑒𝐺𝐹𝑃−5−𝐻𝑇1𝐴])
[𝑀𝑂𝑃−𝑒𝐺𝐹𝑃−5−𝐻𝑇1𝐴]
   (14) 
If we divide both, the numerator and the denumerator in eq. (6b) by the total concentration of 
red-labeled molecules:  
𝐾𝑑 =  
([𝑀𝑂𝑃−𝑒𝐺𝐹𝑃]𝑡𝑜𝑡𝑎𝑙− [𝑀𝑂𝑃−𝑒𝐺𝐹𝑃−5−𝐻𝑇1𝐴])∙([5−𝐻𝑇1𝐴−𝑇𝑜𝑚𝑎𝑡𝑜]𝑡𝑜𝑡𝑎𝑙− [𝑀𝑂𝑃−𝑒𝐺𝐹𝑃−5−𝐻𝑇1𝐴])
[5−𝐻𝑇1𝐴−𝑇𝑜𝑚𝑎𝑡𝑜]𝑡𝑜𝑡𝑎𝑙
[𝑀𝑂𝑃−𝑒𝐺𝐹𝑃−5−𝐻𝑇1𝐴]
[5−𝐻𝑇1𝐴−𝑇𝑜𝑚𝑎𝑡𝑜]𝑡𝑜𝑡𝑎𝑙
,                 (15) 
and rearrange eq. (15), the following expression is obtained: 
𝐾𝑑 =  
([𝑀𝑂𝑃−𝑒𝐺𝐹𝑃]𝑡𝑜𝑡𝑎𝑙− [𝑀𝑂𝑃−𝑒𝐺𝐹𝑃−5−𝐻𝑇1𝐴])∙(1− 
[𝑀𝑂𝑃−𝑒𝐺𝐹𝑃−5−𝐻𝑇1𝐴]
[5−𝐻𝑇1𝐴−𝑇𝑜𝑚𝑎𝑡𝑜]𝑡𝑜𝑡𝑎𝑙
)
[𝑀𝑂𝑃−𝑒𝐺𝐹𝑃−5−𝐻𝑇1𝐴]
[5−𝐻𝑇1𝐴−𝑇𝑜𝑚𝑎𝑡𝑜]𝑡𝑜𝑡𝑎𝑙
.                                  (16)  
By expressing the molar concentration in terms of the average number of molecules in the 
OVE, c = n/VOVE, where n is the number of moles, n = (N/NA), eq. (16) becomes: 
𝐾𝑑 =  
(
𝑁𝑔
𝑡𝑜𝑡𝑎𝑙
𝑁𝐴∙𝑉𝑂𝑉𝐸
 
− 
𝑁𝑔𝑟
𝑁𝐴∙𝑉𝑂𝑉𝐸
 
) ∙(1− 
𝑁𝑔𝑟
𝑁𝑟
𝑡𝑜𝑡𝑎𝑙)
𝑁𝑔𝑟
𝑁𝑟
𝑡𝑜𝑡𝑎𝑙
,                               (17) 
which after introducing RCCA = 
Nrg
Nr
total, gives:  
𝐾𝑑 =  
(𝑁𝑔
𝑡𝑜𝑡𝑎𝑙− 𝑁𝑔𝑟)∙
1
𝑁𝐴∙𝑉𝑂𝑉𝐸
∙(1− 𝑅𝐶𝐶𝐴)
𝑅𝐶𝐶𝐴
 = =  
(𝑁𝑔
𝑡𝑜𝑡𝑎𝑙− 𝑁𝑟
𝑡𝑜𝑡𝑎𝑙∙𝑅𝐶𝐶𝐴)∙(1− 𝑅𝐶𝐶𝐴)
𝑅𝐶𝐶𝐴
 ∙
1
𝑁𝐴∙𝑉𝑂𝑉𝐸
    .             (18) 
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4 RESULTS 
 
4.1 OPIOIDS DIFFER IN THEIR ABILITY TO POTENTIATE HETERODIMER 
FORMATION BETWEEN MOP AND 5-HT1A AND AFFECT SECOND 
MESSENGER SYSTEM DIFFERENTLY (PAPER I) 
 
Non-peptide opioids potentiate MOP and 5-HT1A heterodimerization to a different extent. 
CLSM imaging showed clear co-localization of both receptors, MOP-eGFP and 5-HT1A-
Tomato, in the plasma membrane in both, the HEK 293 and the PC12 cells (Fig. 4B). It also 
showed that treatment with non-peptide opioids did not cause internalization, neither of 
individual receptors, nor of receptor heterodimers. This is in contrast with the effect caused by 
treatment with the opioid peptide DAMGO, which promoted MOP internalization, but not 
internalization of the MOP-eGFP–5-HT1A-Tomato heterodimers. 
FCCS analysis, performed on cells selected to express similar levels of both receptors, 
NMOP = (27  6) and N5-HT1A = (25  3), corresponding to an average concentrations of: cMOP = 
(320  70) nM and c5-HT1A = (300  40) nM, respectively, showed that MOP-eGFP and 5-HT1A-
Tomato receptors not only co-localized in the plasma membrane, but also formed heterodimers, 
as evidenced  by tCCCs. On average about 33 % (RCCA = 0.33) of the 5-HT1A-Tomato 
receptors were bound in heterodimer complexes with MOP-eGFP in untreated cells. From 
these measurements, an apparent dissociation constant for the heterodimers was determined, 
𝐾𝑑
𝑎𝑝𝑝
 = (440  70) nM. 
Moreover, FCCS showed that treatment with different concentrations of fentanyl 
increased the number of heterodimers between MOP-eGFP and 5-HT1A-Tomato (Fig. 5A and 
B). Fentanyl treatment had a dose dependent increase in heterodimers, as evident from the 
increase in RCCA from 𝑅𝐶𝐶𝐴𝐹𝑒𝑛𝑡𝑎𝑛𝑦𝑙
50 𝑛𝑀  = 0.42  0.09, which was not significantly different 
from the RCCA value measured in untreated cells (P = 0.067), to 𝑅𝐶𝐶𝐴𝐹𝑒𝑛𝑡𝑎𝑛𝑦𝑙
500 𝑛𝑀  = 0.49  0.09 
(P = 0.028) in cells treated with 500 nM fentanyl, and 𝑅𝐶𝐶𝐴𝐹𝑒𝑛𝑡𝑎𝑛𝑦𝑙
750 𝑛𝑀  = 0.62  0.07 (P = 3.16E-
7) in cells treated with 750 nM fentanyl. From the experimentally determined concentration of 
heterodimers and the known concentration of fentanyl, the effect of fentanyl on the extent of 
MOP-eGFP and 5-HT1A-Tomato heterodimerization could be quantified (Fig. 5B, solid red 
line). Considering the concentration of heterodimer complexes as a dependent variable, the 
concentration of fentanyl as an independent variable and assuming no competing reactions, the 
concentration of fentanyl at which the number of heterodimers would be doubled was 
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determined to be (1.90 ± 0.05) µM 105. Unexpectedly, treatment with 1 µM fentanyl showed a 
decrease, rather than the expected increase in the concentration of heterodimers (Fig. 5B, 
dashed red line) and the RCCA decreased to 0.45 (SD = 0.11, P = 0.004). This suggested that 
other processes, such as receptor homodimer formation and/or higher-order receptor 
heterooligomer formation may occur at high fentanyl concentrations 106 and/or that fentanyl at 
such high concentrations may be toxic to cells 107.   
With this in mind, no concentrations higher than 750 nM were investigated and this 
concentration was selected in further studies to compare the effects of different opioids. FCCS 
showed that for treatment with 750 nM: fentanyl, the RCCA was 𝑅𝐶𝐶𝐴𝐹𝑒𝑛𝑡𝑎𝑛𝑦𝑙
750 𝑛𝑀  = 0.62  0.07, 
which was significantly different from the RCCA value measured in untreated cells (P = 3.16E-
7); 𝑅𝐶𝐶𝐴𝑀𝑜𝑟𝑝ℎ𝑖𝑛𝑒
750 𝑛𝑀  = 0.47  0.08 (P = 1.65E-4); 𝑅𝐶𝐶𝐴𝐶𝑜𝑑𝑒𝑖𝑛𝑒
750 𝑛𝑀  = 0.59  0.07 (P = 5.25E-7) and 
𝑅𝐶𝐶𝐴𝑂𝑥𝑦𝑐𝑜𝑑𝑜𝑛𝑒
750 𝑛𝑀  = 0.47  0.09 (P = 0.0117) (Fig. 5C). Moreover, the RCCA value measured 
for cells treated with fentanyl was significantly higher than that measured in cells treated with 
equimolar concentrations of morphine (P = 2.48E-4) or oxycodone (P = 6.99E-4), but not 
significantly higher than that for codeine (P = 0.24). The difference in RCCA values measured 
in cells treated with codeine was significantly higher than that in cells treated by morphine (P 
= 3.66E-3). Based on these measurements and using eq. (14), the apparent dissociation 
constants for the MOP-eGFP–5-HT1A-Tomato heterodimers in the presence of equimolar 
concentrations (750 nM) of different non-peptide opioids could be determined: 𝐾𝑑,𝐹𝑒𝑛𝑡𝑎𝑛𝑦𝑙
𝑎𝑝𝑝
 = 
(80  70) nM, 𝐾𝑑,𝑀𝑜𝑟𝑝ℎ𝑖𝑛𝑒
𝑎𝑝𝑝
 = (200  70) nM, 𝐾𝑑,𝐶𝑜𝑑𝑒𝑖𝑛𝑒
𝑎𝑝𝑝
 = (100  70) nM and 𝐾𝑑,𝑂𝑥𝑦𝑐𝑜𝑑𝑜𝑛𝑒
𝑎𝑝𝑝
 = 
(200  70) nM. Likewise, the apparent heterodimer dissociation constants in the presence of 
different concentrations of fentanyl were determined to be: 𝐾𝑑,50 𝑛𝑀 𝐹𝑒𝑛𝑡𝑎𝑛𝑦𝑙
𝑎𝑝𝑝
= (260  70) nM, 
𝐾𝑑,500 𝑛𝑀 𝐹𝑒𝑛𝑡𝑎𝑛𝑦𝑙
𝑎𝑝𝑝
= (180  70) nM, 𝐾𝑑,750 𝑛𝑀 𝐹𝑒𝑛𝑡𝑎𝑛𝑦𝑙
𝑎𝑝𝑝
= (80  70) nM, and 𝐾𝑑,1 µ𝑀 𝐹𝑒𝑛𝑡𝑎𝑛𝑦𝑙
𝑎𝑝𝑝
= 
(220  70) nM. 
Treatment with non-peptide opioids increase to a different extent the brightness of eGFP 
and Tomato. Prolonged treatment with non-peptide opioids increased eGFP brightness, as 
evident from the measured counts per second and per molecule (CPM). In untreated cells, 
average eGFP brightness was 𝐶𝑃𝑀𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑
𝑒𝐺𝐹𝑃  = (1.1  0.3) kHz. In treated cells, eGFP 
brightness nearly doubled, showing statistically significant difference for all treatments: 
𝐶𝑃𝑀𝐹𝑒𝑛𝑡𝑎𝑛𝑦𝑙
𝑒𝐺𝐹𝑃  = (1.9  0.7) kHz (P = 0.015), 𝐶𝑃𝑀𝑀𝑜𝑟𝑝ℎ𝑖𝑛𝑒
𝑒𝐺𝐹𝑃  = (2.0  0.5) kHz (P = 9.6E-3), 
𝐶𝑃𝑀𝐶𝑜𝑑𝑒𝑖𝑛𝑒
𝑒𝐺𝐹𝑃  = (1.9  0.5) kHz (P = 5.8E-3), and  𝐶𝑃𝑀𝑂𝑥𝑦𝑐𝑜𝑑𝑜𝑛𝑒
𝑒𝐺𝐹𝑃  = (1.8  0.7) kHz (P = 0.027). 
Interestingly, an increase in Tomato brightness was also observed in cells treated with 750 nM 
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fentanyl or morphine, but not in cells treated with codeine or oxycodone. However, the increase 
in Tomato brightness was not as pronounced as for eGFP, and changed from 𝐶𝑃𝑀𝑈𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑
𝑇𝑜𝑚𝑎𝑡𝑜  = 
(0.8  0.2) kHz in untreated cells to: 𝐶𝑃𝑀𝐹𝑒𝑛𝑡𝑎𝑛𝑦𝑙
𝑇𝑜𝑚𝑎𝑡𝑜  = (1.1  0.3) kHz (P = 0.021) for treatment 
with 750 nM fentanyl; 𝐶𝑃𝑀𝑀𝑜𝑟𝑝ℎ𝑖𝑛𝑒
𝑇𝑜𝑚𝑎𝑡𝑜  = (1.3  0.3) kHz (P = 3.0E-3) for treatment with 750 nM 
morphine, whereas it remained unchanged (within the limits of the experimental error) for 
treatment with 750 nM codeine, 𝐶𝑃𝑀𝐶𝑜𝑑𝑒𝑖𝑛𝑒
𝑇𝑜𝑚𝑎𝑡𝑜 = (1.0  0.3) kHz (P = 0.20), or 750 nM 
oxycodone, 𝐶𝑃𝑀𝑂𝑥𝑦𝑐𝑜𝑑𝑜𝑛𝑒
𝑇𝑜𝑚𝑎𝑡𝑜  = (0.9  0.3) kHz (P = 0.12). It is hard to say with certainty why 
the brightness of fluorescence reporters has changed following treatment with non-peptide 
opioids, two potential processes: receptor homodimerization and fluorescence lifetime change 
due to environmental changes during signal transduction, can independently and jointly cause 
such effects. 
Non-peptide opioids differ in the extent to which they activate major signal transduction 
pathways. In order to assess the effects of non-peptide opioids on the second messenger 
pathways in HEK 293 cells expressing MOP-eGFP and 5-HT1A-Tomato, phosphorylation of 
MAPKs ERK1/2 and p38 was investigated.  MOP activation has been shown to trigger 
phosphorylation of both, ERK1/2 108 and p38 109. Western blot analysis showed an increase in 
phosphorylated ERK1/2 and p38 in cells that had been treated with 750 nM of morphine, 
oxycodone, codeine or fentanyl, when compared to untreated cells (Fig. 5D and E). Fentanyl 
elicited the strongest ERK1/2 activation (mean = 1.156, SD = 0.183, P = 8.52E-4), while 
oxycodone barely activated it (mean = 0.506, SD = 0.139, N.S). In contrast, oxycodone elicited 
the strongest p38 activation (mean = 1.441, SD = 0.517, P = 0.025), while the effects of 
fentanyl, morphine, and codeine were similar. Interestingly, LC-MS/MS metabolite analysis 
indicated that these effects are likely attributed to the primary non-peptide opioid compounds 
in their own right, as there were no common opioid metabolites detected neither in the cell 
culture medium nor in the cell lysate. 
Non-peptide opioids elicit different intracellular Ca2+ signaling dynamics. Time-lapse CLSM 
imaging of intracellular Ca2+ levels using the cell-permeant Fura Red ratiometric dye showed 
that stimulation with equimolar concentration of different non-peptide opioids acutely induced 
different changes in the intracellular Ca2+ levels in HEK293 cells expressing MOP-eGFP and 
5-HT1A-Tomato (Fig. 5F). In untreated cells, intracellular Ca
2+ showed no fluctuations in 
concentration. Following addition of 750 nM morphine, the stationary state levels did not 
change, but the stationary state appeared to have lost its stability and sinusoidal oscillations in 
Ca2+ levels with smoothly increasing amplitudes and a period of about 5 min, emerged.  
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Figure 5. Results from non-peptide opioid study in HEK 293 cells expressing MOP-eGFP and 5-HT1A-
Tomato (paper I) A) RCCA analysis shows that prolonged treatment (18 h) with fentanyl induces a dose-
dependent increase in MOP-eGFP and 5-HT1A-Tomato heterodimer formation. For fentanyl concentrations above 
1 µM, the extent of heterodimer formation drops. B) Fentanyl dose response curve calculated from the 
experimentally obtained RCCA values in A and the known concentrations of Fentanyl. C) Prolonged treatment 
with non-peptide opioid drugs at 750 nM promotes hetero dimer formation between MOP-eGFP and 5-HT1A-
Tomato, as evident by the recorded RCCA. D) Western blot analysis shows that prolonged treatment with non-
peptide opioids activates ERK1/2 signaling pathways differently. E) p38 activation varies after prolonged 
exposure to non-peptide opioids, as evident by western blot analysis. F) CLSM time-lapse imaging of Ca2+ levels 
(Fura Red, dark violet) in HEK293 cells expressing MOP-eGFP (green) and 5-HT1A-Tomato (red) after 40 min 
treatment with 750 nM oxycodone. White arrows indicate changes in Fura Red fluorescence intensity, reflecting 
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changes in the concentration of Ca2+ ions. Scale bar 20 µm. G) Fluctuations in Fura Red fluorescence intensity 
over time following initial treatment with 750 nM of non-peptide opioid drugs. The box-and-whisker Plot (A and 
C): the solid line shows the mean value, the dashed line shows the median, box represents the standard deviation 
and the whiskers give the 5-95 percentile. The staple-whisker plots (D and E): staples show the mean value, the 
solid line the median and the whiskers the standard deviation. All statistical analysis are two-tailed P-value (P) 
with P = 0.05 used as the cutoff for significance.  
Treatment with 750 nM codeine caused a pronounced increase in Fura Red fluorescence 
intensity, indicating that intracellular Ca2+ levels have decreased, and induced oscillations in 
intracellular Ca2+ levels. However, these oscillations showed features of so-called relaxation 
oscillations 110, which are characterized by a relatively long relaxation period during which the 
system remained in the stationary state, alternating with a short period in which abrupt decrease 
in fluorescence intensity, i.e., increase in intracellular Ca2+ level was observed. Treatment with 
750 nM fentanyl did not cause any oscillations in intracellular Ca2+ levels, but a four-fold 
increase in Fura Red fluorescence intensity was noted, indicating that intracellular Ca2+ levels 
decreased markedly following fentanyl addition. Finally, treatment with 750 nM oxycodone 
increased somewhat Fura Red fluorescence intensity, and small-amplitude relaxation 
oscillations with gradually increasing amplitudes and a period of about 5 min were observed 
(Fig. 5G). 
4.2 5-HT1A AGONISTS ABOLISH MORPHINE INDUCED MOP AND 5-HT1A 
HETERODIMERS (PAPER II) 
After establishing that chronic exposure to non-peptide opioid drugs did potentiate the 
formation of MOP-eGFP and 5-HT1A-Tomato heterodimers, the objective was to see how 
treatment with 5-HT1A agonists would affect these interactions. For this study, morphine was 
used to potentiate heterodimer formation between MOP-eGFP and 5-HT1A-Tomato. Five 
agonists to 5-HT1A were chosen, namely serotonin (5-HT), buspirone and three novel drug 
candidates that are analogs to buspirone (Fig. 6).  
 
Figure 6. 5-HT1A partial agonists: Serotonin 3-(2-Aminoethyl)-1H-indol-5-ol, Buspirone (8-[4-(4-pyrimidin-
2-ylpiperazin-1-yl)butyl] -8-azaspiro[4.5] decane-7,9-dione), B2 (8-methyl-2-{4-[4- (pyrimidin-2-yl) piperazin-1-
yl] butyl}-2,8-diazaspiro [4.5] decane-1,3-dione), B3 (8-{4-[4-(pyrimidin-2-yl) piperazin-1-yl] butyl} -8-
azaspiro[4.5] decane-1,4-dione) and B5 (3-[4-[4-(4,6-dimethylpyrimidin-2-yl) piperazin-1-ium-1-yl] butyl]-5,8,8- 
trimethyl -3-azabicyclo[3.2.1] octane-2,4-dione;chloride;hydrochloride 
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As before, CLSM imaging showed co-localization of the receptors on the plasma membrane 
with neither of the compounds inducing internalization. In accordance with paper I, FCCS 
measurements showed an increase in the average number of heterodimer complexes in cells 
treated with 750 nM of morphine for 18 h. Treatment with 750 nM of 5-HT or buspirone 
reduced the average number of MOP-eGFP-5-HT1A-Tomato heterodimers, as compared to 
untreated cells, however, only the decrease from the buspirone cohort showed statistical 
significance. Moreover, FCCS analysis showed that co-treatment with equimolar 
concentrations (750 nM) of morphine and 5-HT1A agonists significantly reduced the number 
of MOP-eGFP-5-HT1A-Tomato heterodimers, as compared to cells treated with 750 nM of 
morphine. Albeit to different extents, with the novel busprione analog B2 significantly reducing 
the average number of heterodimers to 21 %, in the presence of equimolar concentrations of 
morphine, which was the lowest RCCA value calculated for any treatment cohort, including 
untreated (Fig. 7A). Brightness (CPM) analysis showed that treatment with 5-HT, morphine 
and co-treatment with equimolar concentrations of 5-HT and morphine significantly increased 
the brightness of eGFP (Fig. 7B). Whereas, 5-HT, morphine, buspirone and co-treatment with 
morphine and 5-HT or busprione significantly increased the brightness of Tomato (Fig. 7C).  
Western blot analysis of ERK1/2 and p38 MAPK signaling showed that all treatment strategies 
increased the phosphorylation of both ERK1/2 and p38, to different extents. Treatment with 
buspirone, B2, B3 and B5 had a significant increase in ERK1/2 activation, as had co-treatment 
with morphine and busprione or B2. Moreover, significant activation of p38 was observed in 
cells treated with 5-HT and busprione, as well as in cells co-treated with morphine and 5-HT.   
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Figure 7. Results from dual agonist study in HEK 293 cells expressing MOP-eGFP and 5-HT1A-Tomato 
(paper II) A) RCCA data shows that treatment with either or both 5-HT1A or MOP agonist at 750 nM significantly 
changes the number of heterodimer complexes between the receptor, as compared to untreated cells. Additionally, 
all RCCA values recorded fall within the negative and positive FCCS controls. B) Brightness analysis (CPM) of 
eGFP from the same measurements as in A show an increase in eGFP brightness for treatment with serotonin, 
morphine and co-treatment with morphine and serotonin. C) Brightness analysis of Tomato from the same 
measurements as in A show an increase in brightness for all treatment cohorts except co-treatment with morphine 
and novel buspirone analogs: B2, B3 and B5. 
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4.3 OPIOID RECEPTORS ARE LARGLEY EXCLUDED FROM GM1 
GANGLIOSIDE-ENRICHED DOMAINS  (PAPER III) 
 
In this study, two different FCCS approaches were applied to study the dynamics between GM1 
ganglioside-enriched domains and opioid receptors. Namely, the interactions between MOP-
Tomato and BODIPY® FL C5-ganglioside GM, in transfected PC12 cells and PC12 cells 
expressing MOP-eGFP and the GM1-specific cholera toxin B subunit conjugated with Alexa 
Fluor® 647 (CTxB-AF647). FCCS measurements on PC12 cells expressing MOP-Tomato 
showed no interaction between the receptor and BODIPY® FL C5-ganglioside GM. Similarly, 
no interaction was detected in PC12 cells between MOP-eGFP and CTxB-AF647. In addition, 
FCCS was also applied to quantitatively characterize the interactions between BODIPY® FL 
C5-ganglioside GM and CTxB-AF647 in solution and on live PC12 cells. The solution 
measurements yielded an apparent equilibrium constant Kd = (2±1) µM, while the PC12 cell 
measurements produced a RCCA value which, when compared to positive and negative FCCS 
control PC12 cells, indicated significant binding between the two compounds. FCCS control 
cells were generated by transfecting cells to express either freely diffusing eGFP and Tomato 
(negative control) or eGFP-Tomato heterodimers (positive control). Although first introduced 
in this paper, the FCCS positive and negative control cells were used as controls in both paper 
I and II. To ensure that fluorescence labeling did not affect the function of the opioid receptors, 
both MOP and KOP (kappa opioid receptor) where expressed in PC12 cells with eGFP 
genetically fused to the N-terminal (previous experiments had C-terminal eGFP tag). 
Comparison of long and short decay times showed no significant difference regarding labeling 
site on MOP and KOP receptors (Fig. 8). 
  
 
Figure 8. Expression of MOP in PC12 cells. A) MOP with C-terminal eGFP tag. B) MOP with N-termial eGFP 
tag. C) MOP with C-terminal Tomato tag. All scale bars 10 µm. 
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4.4 THE DYNAMIC EQUILIBRIUM BETWEEN MONOMERIC, OLIGOMERIC 
AND AGGREGATED FROM INFLUENCE THE EFFICACY OF CELL-
PENETRATING PEPTIDES (PAPER IV) 
 
In this study, FCS was first applied to map the dynamics of the cell-penetrating peptide PepFect 
14 (PF14). Measurements with FCS, in solution, showed that PF14K-CR6G (FP14 conjugated 
with carboxyrhodamine 6G) had a propensity to self-associate into oligomers and aggregates, 
that where four orders of magnitude larger than the monomers. FCS also revealed that the 
process of PF14K-CR6G self-association was dependent on protonation (pH) and 
concentration. Additionally, FCS measurements performed on the apical plasma membrane of 
live PC12 cells and in their surrounding solution showed that PF14K-CR6G accumulated on 
the plasma membrane over time, which was also confirmed via CLSM imaging, and exhibited 
a wider range of differently sized oligomers on the plasma membrane, as compared to solution. 
Finally, FCS measurements revealed that the diffusion time of Cy5 labeled small interfering 
RNA (Cy5-siRNA) increased with the increase in PF14 concentration. The interaction between 
Cy5-siRNA and PF14K-6G was further probed via FCCS, which showed that Cy5-siRNA and 
PF14K-6G more readily formed complexes on the plasma membrane of live PC12 cells than 
in solution.  
 
4.5 CARBOHYDRATE EPITOPES INFLUENCE PROTEIN UPTAKE OVER THE 
PLASMA MEMBRANE  
 
Galactose-α-1,3-galactose (α-Gal) presenting bovine serum albumin (BSA) was found to be 
more readily absorbed by immature monocyte-derived dendritic cells (iMDDCs), than BSA 
without α-Gal. CLSM imaging of fixed iMDDCs showed the presence of Alexa Fluor® 488 
conjugated BSA- α-Gal in cytoplasmic vesicles, both after 1 and 4 h incubation. Whereas, 
incubation with Alexa Fluor® 488 conjugated BSA showed no signs of vesicle formation in 
fixed iMDDCs, after 1 and 4 h. The results corroborated data acquired via flow cytometry, 
which indicated that carbohydrate epitopes are more important for uptake than protein size. 
This was shown by comparing the uptake of BSA- α-Gal and bovine thyroglobulin (bTG) in 
iMDDCs from healthy individuals. Despite bTG having a molecular weight almost ten times 
that of BSA- α-Gal no differences in uptake could be observed. 
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5 DISCUSSION 
 
The ever-growing advances in the field of fluorescence microscopy have allowed scientists to 
quantitatively and with high precision elucidate many of the molecular interactions that 
underlie the complex dynamic of a living cell 111-113. In my work, one such technique was 
predominantly used, the quantitative time-resolved fluorescence technique with single 
molecule sensitivity called Fluorescence Correlation Spectroscopy (FCS) and its dual color 
version Fluorescence Cross-Correlation Spectroscopy (FCCS).  
FCCS was fundamental in testing the hypothesis that prolonged exposure to non-peptide 
opioid drugs promoted heterodimer formation between MOP and 5-HT1A
66. The high spatial 
and temporal resolution of FCCS, coupled to it being for most parts a non-destructive technique 
made it possible to quantitatively characterize the interactions between the two receptors in live 
cells, as well as the effects of  the most commonly used non-peptide opioid drugs: morphine, 
oxycodone, codeine and fentanyl, on the extent of these interactions (Paper I). Calculation of 
the RCCA revealed that on average around 33% (RCCA = 0.33) of 5-HT1A-Tomato receptors 
had formed heterodimer with MOP-eGFP. This value might not be physiologically relevant 
and might only apply to this cell model, with its expression level, where the average 
concentration of (270  60) nM for MOP-eGFP and (250  30) nM for 5-HT1A-Tomato. 
Transfecting cells to express proteins of interest through powerful promotors does lead to 
strong over-expression. However, this is usually a transient effect. Stably transformed cells do 
not yield as high expression as transiently transfected cells, which is why only stable cell lines 
where investigated (paper I and II). Moreover, all non-peptide opioid drugs were found to 
significantly increase the number of MOP and 5-HT1A heterodimer complexes, with fentanyl 
showcasing the strongest contribution to the heterodimer formation between the receptors. 
Although, the concentrations of 750 nM fentanyl might be relatively high, given that fentanyl 
achieves analgesic effect at around 1.8 – 4.4 nM (blood plasma concentration), in opioid-naive 
postoperative patients 114. It is important to point out that treatment for cancer pain measured 
concentrations as high as 530 nM in patients 107, thus placing the concentrations used in this 
study in a physiologically relevant range. Moreover, in this study only equimolar 
concentrations of opioids where compared. We did not consider equipotent concentrations of 
opioids. Although there are several conversion tables for opioids, they are perceived as 
unreliable 115. The few studies that have addressed opioid equianalgesic dose/potency ratios are 
heterogeneous in regards to size, subjects, specific aims, settings and study method 116. Rennick 
et al. concluded from their findings that there is no true universal way to accurately perform 
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equianalgesic conversions for opioids 117. Morphine and codeine showed significant 
differences in their potency to stabilize MOP–5-HT1A heterodimers. Surprisingly, exposure to 
codeine had an average stronger effect than morphine, both in regards to heterodimer formation 
and changes in calcium signaling dynamics. An observation that is contrary to the general view 
that codeine is an inactive prodrug with a low affinity for MOP, with analgesic effect only after 
metabolic conversion to morphine 118-120 and dihydrocodeine-6-O-gluconoride 121,122. Codeine 
as an active substance is in line with the fact that HEK 293 cells do not express the CYP2D6 
gene (https://www.proteinatlas.org/ENSG00000100197-CYP2D6/cell, 2019-10-10) needed to 
metabolize codeine 123. LC-MS/MS analysis showed that there were no traces of codeine 
metabolites, neither in the cell medium nor in the cell lysates. The analysis of the cell medium 
showed the presence of codeine, but the analysis of cell lysate failed to measure any compound. 
This was most likely due to the minute quantities of drugs present in cell lysate. The opioid-
induced increase in heterodimer interactions between MOP-eGFP and 5-HT1A-Tomato might 
alter intracellular signaling and might contribute to neuroplastic changes previously  linked to 
chronic pain 124. The activation of presynaptic MOP and 5-HT1A can in a cooperative manner 
inhibit the release of GABA onto the periaqueductal gray (PAG) 1. Activation of the GABAA 
receptors in neurons projecting into the PAG exhibits a net pronociceptive effect 125. Thus, the 
opioid induced heterodimer formation between MOP and 5-HT1A could hamper GABA release 
by rendering both receptors inactive. Which could potentially promote pronociceptive 
pathways via GABAA receptors.  
While prolonged exposure to MOP agonists seems to induce receptor heterodimerization 
the opposite effect was observed for prolonged exposure with 5-HT1A agonists, particularly the 
novel busprione analog B2 (paper II). B2 has a similar structure to buspirone, with a key 
difference being an additional nitrogen atom on B2. According to the QSAR model, the charge 
associated with nitrogen adds significant influence on the activity of the compound, which is 
in line with the obtained FCCS data. Additional structural differences between buspirone and 
B2 are the potential to form additional hydrogen bonds, compound bulk properties and spatial 
polarity, which all might influence the overall performance of the compound. Brightness 
analysis (CMP) showed a significant two-fold increase in Tomato brightness in the cells treated 
with serotonin and buspirone, as well as for cells co-treated with morphine and serotonin or 
busprione. Potentially, this can be explained by agonist-induced 5-HT1A homodimerization, 
although further studies would be needed to confidently draw that conclusion. In accordance 
with our hypothesis, we demonstrated that prolonged (18h) morphine exposure induced 
heterodimer formation between MOP-eGFP and 5-HT1A-Tomato could be relaxed by co-
administrating an agonist to 5-HT1A. The diminished degree of measurable MOP and 5-HT1A 
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heterodimers, in the presence of morphine and any of the tested 5-HT1A agonists, suggest that 
activation of 5-HT1A is a potential key mechanism in preventing adverse effects of prolonged 
opioid treatment. Buspirone has been shown to counteract OIH and reverse opioid tolerance 
and the rewarding effects of opioids in animal trials 67-69. Haleem et al suggested that this was 
due to buspirones agonistic effects on 5-HT1A and antagonistic effects on dopamine D2 
receptor 67. 
The hypothesis formulated by Kosek et al. suggested that sensitization of pronociceptive 
pathways could be caused by the heterodimer formation between MOP and 5-HT1A. Which 
could contribute to changes in neuroplasticity, via altered cellular signaling. In the HEK 293 
cell model, changes in cell signaling were observed for prolonged exposure to all non-peptide 
opioids tested (paper I). Fentanyl elicited the highest activation of the ERK1/2 pathway and a 
notable activation of p38, whiles acutely decreasing intracellular calcium levels. Notably, 
oxycodone had the weakest, although significant, increase in heterodimer complexes, but the 
strongest activation of the p38 MAPK pathway.  This finding is in line with the observation 
that rats exhibited increased p38 activity during chronic oxycodone exposure 126 and that opioid 
reward behavior was modulated by p38 activation in mice 127, while KOP  induced p38 
activation was found to reinstate drug seeking behavior in mice 128. Activation of p38 could be 
very relevant for the observed adverse and addictive qualities of oxycodone, as a recent study 
argued that the addictive qualities of oxycodone outweighed its benefits as a prescription 
drug129.   
Both morphine and buspirone have been shown to activate MAPK signaling pathways 
130-133. Therefore, it is reasonable to expect a higher concentration of phosphorylated ERK1/2 
and p38 in all treatment cohorts as compared to the untreated (paper II). The activation of 
EK1/2 has been linked to opiate addiction 133 and activation of p38 has been proven 
instrumental in MOP internalization and maintenance of MOP heterodimers 109. Prolonged 
morphine use has been shown to induce changes at the receptor level and alter CREB activation 
through MAPK/ERK, leading to adverse opioid effects 131. In addition, morphine has been 
found to increase ERK phosphorylation via a dopamine D1 receptor dependent mechanism 67. 
Dopamine D1 receptors are known to modulate dopamine D2 receptor dependent events 134, 
which could potentially be one of the mechanisms through which buspirone reverses adverse 
opiate effects, as suggested by Haleem et al., although further research would be needed to 
fully map the extent of these interactions.  
The picture that emerges is that the dynamics of GPCR-interactions on the plasma 
membrane are of paramount importance for complex biological processes, like pain 
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modulation. One key aspect of the plasma membrane explored in this thesis it the feature of 
compartmentalization (paper III). Compartmentalization allows physical separation of 
molecules via inclusion / exclusion from specific domains. Which in turn affects their local 
concentration, chemical equilibrium and interaction kinetics. FCS and FCCS measurements 
elucidated a model for MOP organization, which saw it associate with cholesterol and GPI-
enriched domains whiles being excluded from GM1 ganglioside-enriched domains.  In 
contrast, 5-HT1A has been shown to associate with GM1 enriched domains 
135 whiles, treatment 
with exogenous ganglioside GM1 was found to beneficially modulate dopamine and serotonin, 
and restore normal levels of glutamate and GABA 136. Hypothetically, the heterodimerization 
between MOP and 5-HT1A, resulting from prolonged opioid exposure, could hinder 5-HT1A 
from associating with GM1 enriched domains, which could potentially also negatively affect 
pain modulation. Although, this hypothesis would need to be thoroughly tested before any such 
conclusion could be confidently drawn.   
It is clear that innovative approaches are needed for the treatment of chronic pain. One 
such approach, recently published, utilized p38-siRNA loaded nanoparticles to significantly 
alleviate allodynia and reduce microgliosis in rats 137. For such therapies to become well 
established the dynamics of how these nanoparticles interact with cells needs to be well 
characterized. By utilizing FCS / FCCS we successfully characterized how cell-penetrating 
peptide-nanoparticles interacted with the plasma membrane of live cells and how chemical 
factors like pH and concentration affected their self-assembly. We also mapped to a good extent 
the interaction of these nanoparticles with siRNA (paper IV). This research project highlighted 
the great versatility of FCS / FCCS. By employing different labeling strategies targeting either 
PF14, siRNA or both the diffusion properties of PF14 as well as interactions between PF14 
and the plasma membrane or siRNA could be elucidated. How molecules like PF14 self-
assemble is important to know if they are to be used as oligonucleotide delivery vectors.  
Finally, in this thesis we employed the most conventional fluorescence application, 
namely CLSM to study cellular uptake of red meat allergens (paper V). The labeling strategy 
employed in this study used DAPI, Alexa Fluor® 488 and Alexa Fluor® 555, and while 
conventional CLSM is well established there are still pitfalls that can severely affect data 
interpretation. Even though DAPI and Alexa Fluor® 488 are spectrally well separated DAPI 
can crosstalk into the green channel through a process known as photo conversion, as a result 
from illumination with UV-light 138. In addition, Alexa Fluor® 555 is known to be cross-
excited by incident light at 485 ± 10 nm 139.  Taking this into consideration when designing a 
CLSM experiment is paramount for correct imaging. For this study, all of these parameters 
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where carefully scrutinized in order to correctly portray the biological events underlying red 
meat allergy.  
In summation, throughout this thesis quantitative fluorescence techniques have been 
employed to characterize GPCR interactions with other GPCRs and their surroundings, which 
in itself is a notable achievement. GPCR homo/heterodimer complexes have been measured in 
live cells for a handful of GPCRs, e.g. 111-113,140, even though these interactions are important 
targets for drug development. However, some limitations of FCS/FCCS are unavoidable and 
should be discussed. FCS/FCCS cannot account for endogenous non-fluorescent receptors, 
fluorescent protein miss folding, receptor constructs with irreversibly photobleached 
fluorophores or with fluorophores residing for various reasons in dark states. These factors can 
influence calculations derived from measurements. This particular limitation does not impact 
the conclusions of this thesis negatively since differences between the experimentally measured 
values are analyzed. Additional validation of FCS/FCCS was also performed by generating 
positive and negative FCCS control cells (papers I-III), which gave insight into the dynamic 
range of measurable RCCA values from zero to one hundred percent binding. Moreover, 
investigation into receptor-label binding site verified that the location of the fluorescent protein 
binding site did not significantly affect the obtained results (paper III).   
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The work presented in this doctorate thesis focuses on understanding cellular and molecular 
mechanisms that underlie the development of opioid induced hyperalgesia (OIH), with a 
particular emphasis on the role of mu-opioid (MOP) and the serotonin 1 A (5-HT1A) receptor 
heterodimerization. The starting point of our work is the hypothesis that prolonged exposure to 
non-peptide opioids promotes heterodimer formation between MOP and 5-HT1A receptors and 
that altered cellular signaling due to receptor heterodimer formation may contribute to 
neuroplastic changes that, eventually, lead to sensitization of pronociceptive pathways at the 
organism level.  
To challenge this hypothesis, which was formulated based on indirect clinical and 
preclinical evidence, Fluorescence Cross-Correlation Spectroscopy (FCCS), an advanced 
analytical method with high temporal resolution and the ultimate, single-molecule sensitivity, 
was used to quantitatively characterize in live cells interactions between these two G protein-
coupled receptors (GPCRs). In line with the formulated hypothesis, the results showed that 
MOP and 5-HT1A receptors form in the plasma membrane heterodimers with an apparent 
dissociation constant 𝐾𝑑
𝑎𝑝𝑝
 = (440  70) nM). Prolonged exposure to all commonly used non-
peptide opioids tested: fentanyl, morphine, codeine and oxycodone, facilitated MOP and 5-
HT1A heterodimerization and stabilized the heterodimer complexes, albeit to a different extent: 
𝐾𝑑,𝐹𝑒𝑛𝑡𝑎𝑛𝑦𝑙
𝑎𝑝𝑝
 = (80  70) nM), 𝐾𝑑,𝑀𝑜𝑟𝑝ℎ𝑖𝑛𝑒
𝑎𝑝𝑝
 = (200  70) nM, 𝐾𝑑,𝐶𝑜𝑑𝑒𝑖𝑛𝑒
𝑎𝑝𝑝
 = (100  70) nM and 
𝐾𝑑,𝑂𝑥𝑦𝑐𝑜𝑑𝑜𝑛𝑒
𝑎𝑝𝑝
 = (200  70) nM. The non-peptide opioids differed also in the extent to which 
they affected the mitogen-activated protein kinases (MAPKs) p38 and the extracellular signal-
regulated kinase (Erk1/2), with morphine, codeine and fentanyl activating both pathways, 
whereas oxycodone activated p38 but not ERK1/2. Moreover, our work showed that acute 
stimulation with different non-peptide opioids differently affected intracellular Ca2+ levels and 
signaling dynamics.  
Furthermore, we showed that morphine-induced heterodimerization of MOP and 5-HT1A 
can be restrained by co-treatment with buspirone, an agonist at the 5-HT1A receptor, and 
buspirone analogues identified by virtual screening: B2, B3 and B5, keeping the level of 
receptor-receptor heterodimers down to values that are characteristic of untreated cells. In fact, 
buspirone and compound B2 were not only effective in preventing morphine-induced MOP–
5-HT1A heterodimerization, but potentiated also the dissociation of the receptor-receptor 
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complexes bringing the MOP–5-HT1A heterodimer levels down to values below those 
measured in untreated cells. 
In summary, the work conducted under my PhD studies identified MOP–5-HT1A 
heterodimerization as a possible mechanism through which aversive effects of non-peptide 
opioids arise under prolonged use, and has led to the identification of three new compounds, 
buspirone analogs B2, B3 and B5, that may counteract these effects. Further studies are needed 
to establish whether this mechanism is also effective in live animals/humans and to determine 
whether combination therapy with opioids and 5-HT1A agonists may become a new strategy to 
counter opioid induced hyperalgesia and help to preserve the analgesic effects of opioids. 
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